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ABSTRACT 
 
The NF-B2 gene is recurrently mutated and over-expressed in human lymphoid 
malignancies. However, a casual relationship between NF-B2 mutation and 
lymphomagenesis has not been established. It is also unclear how the mutation 
may lead to lymphoid malignancies. Recent studies suggest that nuclear factor B 
inducing kinase (NIK) is suppressed through constitutive proteasome-mediated 
degradation regulated by TRAF3, thus preventing processing of the NF-B2 
precursor protein p100 to release p52. Here we demonstrate that BAFF Receptor, 
a member of the TNF Receptor family, interact with TRAF1, a member of TRAF 
family. This interaction activates NF-B2 via increased degradation of TRAF3 
and stabilization of NIK. Indeed, interference of TRAF1 in lymphoma B cell line 
downregulates p100 processing and lead to decreased survival of B cells. 
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BACKGROUND 
 
Introduction 
 
The inducible regulation of gene expression is a central element of normal 
physiology and is the key to the ability of multicellular organisms to adapt to 
environmental, mechanical, chemical and microbiological stresses. Owing to its 
importance in disease, NF-B has served as a model of cell, tissue and organism 
level responses that are orchestrated through inducible transcription factors. NF-
B plays its most important and evolutionary conserved role in the immune 
system, regulating the expression of inducers and effectors at many point in the 
expensive networks that define responses to pathogens. The reach of NF-B, 
however, extends to transcriptional regulation beyond the confines of the immune 
response, acting broadly to influence gene expression events that impact cell 
survival, differentiation and proliferation. The diversity of biological roles 
fulfilled by NF-B raised several intriguing question about how a limited set of 
signal transduction molecules regulates signaling to NF-kB in all pathway and, 
conversely, how discrete inputs create transcriptional responses tailored to 
particular tissues and organs with the same limited set of regulators.  
The basic scheme of NF-B signaling consists in a series of positive and negative 
regulatory elements. Inducing stimuli trigger IKK activation leading to 
phosphorilation, ubiquitination and degradation of IBs proteins. Released NF-B 
dimers are further activated through various posttranslational modifications and 
translocate to the nucleus where they bind to specific DNA sequences and 
promote transcription of target genes. In its most basic form, therefore, the 
pathway consists of receptor and receptor proximal signaling adaptor molecules, 
the IKK complex, IB proteins and NF-B dimers. 
The NF-B family of transcription factors consists of five members, p50, p52, p65 
(RelA), c-Rel and RelB, encoded by NFKB1, NFKB2, RELA, REL and RELB, 
respectively, which share an N-terminal Rel homology domain (RHD) responsible 
for DNA binding and homo- and heterodimerization (Fig.1). NF-B dimers bind 
to B sites within the promoters/enhancers of target genes, and regulate 
transcription through the recruitment of coactivators and corepressors. The 
transcription activation domain (TAD) necessary for the positive regulation of 
gene expression, is present only in p65, c-Rel and RelB. As they lack TADs, p50 
and p52 may repress transcription unless associated with a TAD-containing NF-
B family member, or other proteins capable of coactivator recruitment. There is 
considerable structural information about NF-κB dimers in both its inactive IκB-
bound form and active DNA bound state. Crystal structures of NF-κB dimers 
bound to κB sites reveal how the immunoglobulin-like domains that comprise the 
RHD contact DNA. The NH2-terminal Ig-like domain confers selectivity for 
certain types of κB sites, whereas the hydrophobic residues within the C-terminal 
domain provide the dimerization interface between NF-κB subunits (Hoffmann et 
al., 2006). In its inactive state, NF-κB dimers are associated with one of three 
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typical IκB proteins, IκBα, IκBβ, or IκBε, or the precursor proteins p100 (NFKB2) 
and p105 (NFKB1). These IκBs maintain NF-κB dimers in the cytoplasm, and are 
crucial for signal responsiveness. There are two inducibly expressed, atypical IκB 
proteins, Bcl-3 (BCL3) and IκBζ (NFKBZ), that function quite differently in the 
regulation of NF-κB. Lastly an alternative transcript of the NFKB1 gene in mouse 
encodes an IκB molecule, IκBγ, whose biological role remains unclear. All IκB 
proteins are characterized by the presence of multiple ankyrin repeat domains 
(Figure 1). The prototypical and most extensively studied member of the family is 
IκBα. IκBα is rapidly degraded during activation of canonical NF-κB signaling 
pathway, leading to the release of multiple NF-κB dimers, although the p65:p50 
heterodimer is likely the primary target of IκBα. The established model of IκB 
function posits that IκBα retains NF-κB dimers in the cytoplasm, thereby 
preventing their nuclear translocation, and subsequent DNA binding; however, the 
situation is actually more complex. The crystal structure of IκBα bound to the 
p65/p50 heterodimer reveals that the IκBα protein masks only the nuclear 
localization sequence (NLS) of p65, whereas the NLS of p50 remains exposed. 
The exposed NLS of p50 coupled with nuclear export sequences (NES) in IκBα 
and p65 leads to constant shuttling of IκBα/NF-κB complexes between the 
nucleus and the cytoplasm, despite steadystate localization that appears almost 
exclusively cytosolic (Ghosh and Karin, 2002). Degradation of IκBα drastically 
alters the dynamic balance between cytosolic and nuclear localization signals to 
favor nuclear localization of NF-κB.  
The noncanonical or alternative NF-κB pathway, proceeds through proteasomal 
processing, rather than degradation, of p100 to p52, thereby liberating p52 
containing NF-κB dimers, that drive a transcriptional response that is distinct from 
that induced by the canonical, IκBα-regulated pathway. In part because IκBα 
degradation and p100 processing regulate different populations of NF-κB dimers, 
canonical and noncanonical NF-κB pathways regulate distinct sets of target genes. 
Degradation of IκB is a rapidly induced signaling event that is initiated upon 
specific phosphorylation of these molecules by activated IKK. The IKK complex 
contains two highly homologous kinase subunits, IKKα/IKK1 and IKKβ/IKK2 
and a regulatory subunit NEMO (NF-κB essential modulator)/IKKγ (Hacker and 
Karin, 2006). Although they are generally found in a heteromeric kinase complex, 
IKKα and IKKβ are somewhat selectively required for specific NF-κB signaling 
pathways. In most canonical NF-κB signaling, downstream of TNFR1, IKKβ is 
both necessary and sufficient for phosphorylation of IκBα on Ser32 and Ser36, 
and of IκBβ on Ser19 and Ser23. While not generally required for IκBα 
phosphorylation and degradation in canonical signaling pathways, IKKα can 
mediate IκBα phosphorylation and appears to play critical role in canonical NF-
κB-dependent transcriptional responses. The noncanonical pathway, conversely, 
depends only on the IKKα subunit, which functions by phosphorylating p100 and 
causing its inducible processing to p52. The noncanonical pathway is activated by 
a subset of TNFR superfamily members, while the canonical pathway is activated 
by a broader and overlapping array of receptors. Phosphorylation of the conserved 
serine residues (DS*GXXS*) in IκB proteins results in their K48-linked 
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polyubiquitination by βTrCP containing Skp1-Culin-Roc1/Rbx1/Hrt-1-F-box 
(SCF) E3 ubiquitin ligase complexes (SCFβTrCP) coordinately with the E2 
UbcH5 (Perkins, 2006). The released NF-κB dimers bind promoter and enhancer 
regions containing κB consensus sequences 5′ GGGRNWYYCC 3′ (N—any base; 
R—purine; W—adenine or thymine; and Y—pyrimidine) (Hoffmann et al., 2006). 
The degenerate nature of the κB site sequence, which shows far greater sequence 
variability than the consensus sequence given here, combined with the varied 
binding preferences of NF-κB dimers yields the large list of NF-κB-regulated 
genes (Gilmore, 2008). Transcription of target genes is further regulated through 
posttranslational modifications of NF-κB that affect the ability of NF-κB dimers 
to interact with transcriptional coactivators. NF-κB-dependent transcription of IκB 
proteins as well as additional mechanisms targeting DNA-bound NF-κB dimers 
terminate the response. 
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Figure 1: The NF-κB, IκB, and IKK Protein Families 
Members of the NF-κB, IκB, and IKK proteins are shown. The number of amino acids in each 
human protein is indicated on the right. Posttranslational modifications that influence IKK activity 
or transcriptional activation are indicated with P, U, or Ac for phosphorylation, ubiquitination, or 
acetylation, respectively. Inhibitory events and phosphorylation and ubiquitination sites on p100, 
p105, and IκB proteins that mediate proteasomal degradation are indicated with red Ps and Us, 
respectively. RHD, Rel homology domain; TAD, transactivation domain; LZ, leucine zipper 
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domain; GRR, glycine-rich region; HLH, helix-loop-helix domain; Z, zinc finger domain; CC1/2, 
coiled-coil domains; NBD, NEMO-binding domain; MOD/ UBD, minimal oligomerization 
domain and ubiquitin-binding domain; and DD, death domain. 
Matthew S. Hayden and Sankar Ghosh. Review. Cell 2008 
 
 
 
Signaling to IKK 
 
A remarkable diversity of stimuli lead to activation of NF-κB. These include both 
endogenous and exogenous ligands, as well as a plethora of physical and chemical 
stresses (Gilmore, 2008). There has been great progress in identifying the protein 
components of pathways that culminate in IKK activation, and many of the 
remaining gaps in our knowledge are being rapidly filled in. However, while the 
identities of these molecules provide critical clues, much remains to be done to 
understand the mechanisms of IKK activation. 
Strikingly, work in numerous signaling pathways leading to NF-κB has 
demonstrated that many of the signaling intermediates, especially those just 
upstream of the IKK complex, are shared. Signaling to NF-κB proceeds through 
intracellular adaptor proteins that provide modularity to NF-κB activation 
pathways and allows their incorporation into various receptor induced signaling 
events. Thus diverse signaling pathways can utilize several shared components for 
both activating and inhibitory pathways. In particular, RIP and TRAF families of 
proteins play similar roles in most pathways that lead to IKK activation (Figure 
2). Although there are exceptions, some of which are noted below, it appears that 
both canonical and noncanonical pathways utilize TRAF family members for 
activation, while only canonical, NEMO-dependent signaling to typical IκBs 
additionally requires RIP proteins. One striking area of growth in the field of NF-
κB signaling has been in the characterization of the role of K63-linked, or 
regulatory, ubiquitination. This area of research began with the biochemical 
characterization of TRAF6 as an E3 ligase that with the E2 ligase Ubc13/Uev1A 
could catalyze the formation of regulatory ubiquitin chains and induce IKK 
activation in vitro (Deng et al., 2000). Subsequently, several signaling 
components have been shown to be modified by K63-linked ubiquitin moieties 
following stimulation (Chen et al., 2006). While there are numerous reports 
demonstrating K63 ubiquitination of various signaling proteins, what continues to 
be lacking is an understanding of how regulatory ubiquitination functions during 
signaling. The delayed kinetics of regulatory ubiquitination and the observation 
that it often targets a very small fraction of any given protein, even within 
signaling complexes, suggest that K63 ubiquitination may be a consequence of 
certain adapters with E3 ligase activity aggregating with other proteins during NF-
κB signaling. Even for particularly robustly and rapidly ubiquitinated adapters 
such as IRAK1 and MALT1, it is unclear whether K63-linked ubiquitination 
occurs before IKK activation and IκBα degradation (Oeckinghaus et al., 2007; 
Windheim et al., 2008). Because K63-linked ubiquitination has not been clearly 
shown to precede IKK activation, it remains to be determined whether these 
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events are intrinsic to the act of signaling, or necessary for the competence of the 
signaling pathways in which they occur. One piece of evidence that strongly 
suggests that K63 ubiquitination does play an active role in signaling is the 
existence of several deubiquitinases (DUBs), most notably A20, that provide 
negative feedback in NF-κB signaling pathways (Chen et al., 2006, Mauro et al., 
2006). More genetic evidence and mechanistic insight are still needed for the 
centrality of regulatory ubiquitination in NF-κB signaling to be unequivocally 
accepted. 
 
 
 
 
 
Figure 2: NF-κB Signaling Pathways 
Following receptor ligation and recruitment of receptor proximal adaptor proteins, signaling to 
IKK proceeds through TRAF/RIP complexes, generally in conjunction with TAK1, leading to 
canonical NF- κB signaling, or through TRAFs and NIK leading to the noncanonical NF-κB 
pathway. IKK activation results in IκB phosphorylation and degradation in the canonical pathway 
or p100 processing to p52 in the noncanonical pathway. Phosphorylated NF-κB dimers bind to κB 
DNA elements and induce transcription of target genes. Matthew S. Hayden and Sankar Ghosh. 
Review. Cell 2008 
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TRAFs - Adapters in Most NF-κB Pathways 
 
TRAFs are key intermediates in nearly all NF-κB signaling pathways; the DNA-
damage response appears to be the only notable exception (Hacker and Karin, 
2006; Scheidereit, 2006). There are seven TRAF proteins that share a C-terminal 
TRAF domain, consisting of a coiled-coil domain that mediates both homo- and 
heterotypic protein-protein interactions. In addition, TRAFs 2–7 have N-terminal 
RING finger domains that may function as E3 ubiquitin ligases by catalyzing the 
transfer of ubiquitin to target proteins a function that has been demonstrated most 
clearly for TRAFs 2 and 6. Among the TRAF proteins, TRAF2, TRAF5, and 
TRAF6 have been most extensively characterized as positive regulators of 
signaling to NF-κB. Research focused on the role of K63-linked ubiquitination in 
NF-κB signaling over the past 7 years has established an important role for TRAF 
E3 ligase activity in the activation of the IKK complex leading to both canonical 
and noncanonical NF-κB pathways and demonstrated the existence of K63 
ubiquitination of multiple pathway components (Chen et al., 2006). In addition to 
NF-κB, TRAF proteins are necessary in several other pathways, such as AP-1, 
and therefore serve as branch points downstream of multiple receptors. The highly 
studied TNFR1 and Toll/IL-1R signaling pathways, have provided the clearest 
evidence of the function of TRAF proteins in IKK activation (Hacker and Karin, 
2006; Hayden et al., 2006). Following binding of TNFα, TRAF2 is recruited to 
TNFR1 through its interaction with TRADD (Hsu et al., 1996). However, despite 
deficiencies in AP-1 activation, TRAF2-deficient cells have relatively intact TNF 
signaling to NF-κB (Yeh et al., 1997). TRAF5 was also shown to interact with the 
TNFR1 signaling complex, yet TRAF5 knockouts also exhibit normal NF-κB 
activation by TNF; TRAF2/5 double knockout cells, however, are defective in 
IKK activation (Nakano et al., 1999; Tada et al., 2001; Yeh et al., 1997). While 
the E3 ligase activity of TRAF2 is thought to be required for IKK activation there 
are several caveats to this assumption. First, deletion of the RING finger domain 
abrogates the ability of TRAF2 to recruit IKK to the receptor complex, making it 
difficult to assess the importance of TRAF2 E3-ligase activity independent of 
adaptor function in NF-κB activation (Devin et al., 2000). Second, knockdown of 
the K63-specific E2 ligase Ubc13 blocks TRAF2 autoubiquitination, but not 
activation of NF-κB, while ubc13−/− macrophages show a similar lack of effect 
on NF-κB activation (Habelhah et al., 2004; Yamamoto et al., 2006a). 
Intriguingly, another group did observe partial defects in TNF signaling to NF-κB 
in ubc13+/− heterozygous macrophages and splenocytes (Fukushima et al., 2007). 
Therefore, in TNFR1 signaling the function of TRAF2 ubiquitin ligase activity 
remains to be more definitively established. It is, however, safe to conclude that 
TRAF2 and TRAF5 are together required for NF-κB activation by TNFR1. 
In Toll/IL-1 signaling TRAF6 is recruited to the receptor complex, and is 
necessary for MyD88-dependent activation of NF-κB by IL-1, and ligands of 
TLR4 (Hacker and Karin, 2006; Hayden et al., 2006). However, like TRAF2, the 
importance of the E3-ligase activity of TRAF6 remains controversial. 
Reconstitution of TRAF6-deficient cells with a TRAF6 mutant lacking the 
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signature motif of E3 RING-finger ligases—that is, the RING finger itself—
completely restored IL-1-induced activation of NF-κB but not activation of JNK 
(Kobayashi et al., 2001). More recently, however, it has been shown that a ring 
finger point mutation of TRAF6 is unable to restore NF-κB activation in TRAF6 
knockout cells (Lamothe et al., 2007). Therefore, the role of the TRAF6 E3 
activity is yet to be definitively established. Deletion of Ubc13, likewise, yields 
conflicting results. Ubc13 knockouts failed to show significant defects in TRAF6-
mediated activation of NF-κB downstream of LPS, IL-1, CD40, or BAFF despite 
impaired MAPK activation (Yamamoto et al., 2006a). Heterozygous splenocytes 
and macrophages, however, showed a mild defect in LPS-induced IκBα 
degradation, less severe than the loss of p38 phosphorylation, and in these mice 
BCR signaling to NF-κB appeared normal (Fukushima et al., 2007). 
In T cell receptor signaling, conditional ablation of Ubc13 resulted in a partial, but 
significant, reduction in NF-κB activation, although activation of JNK and TAK1 
was more severely impaired (Yamamoto et al., 2006b). Therefore, it is probably 
too early to draw a definitive conclusion about the general role of TRAF/Ubc13-
mediated ubiquitination in IKK activation. In addition to TRAF2 and TRAF6, the 
ubiquitin ligase activity of TRAF3 has been reported to regulate NF-κB signaling 
pathways. 
The noncanonical NF-κB pathway is characterized by processing of p100 to p52, 
and by its independence from IKKβ and NEMO. Instead the alternative pathway 
relies on the activation of IKKα by the NF-κB-inducing kinase (NIK) (Hacker and 
Karin, 2006; Scheidereit, 2006). TRAF3, which interacts with receptors that 
trigger the alternative pathway (Hauer et al., 2005), also interacts with NIK and it 
now appears that the activation of NIK is negatively regulated by TRAF3. In the 
resting state, TRAF3 induces NIK ubiquitination and degradation, but upon 
stimulation, TRAF3 undergoes signal-dependent degradation, mediated by other 
TRAF family members, resulting in the accumulation and activation of NIK, and 
consequent activation of the noncanonical pathway (Liao et al., 2004). Recently 
this negative role of TRAF3 has been demonstrated genetically by rescuing the 
lethality of TRAF3-deficient mice by deleting the p100 gene (He et al., 2006). It 
remains unclear how alternative pathway signaling through degradation of TRAF3 
might affect the ability of TRAF3 to fulfill its additional role as a key mediator of 
TLR-induced type I interferon responses (Hacker et al., 2006; Oganesyan et al., 
2006). Thus, TRAF proteins seem to play a crucial role in receptor induced IKK 
activation in both canonical and noncanonical pathways. It remains unclear 
whether they act primarily by catalyzing K63-linked ubiquitination, or as adaptor 
proteins. TRAF proteins may directly recruit the IKK complex through IKKα or 
IKKβ binding (Devin et al., 2001), although in most signaling pathways additional 
IKK recruitment mechanisms have been reported. For example, in antigen 
receptor signaling IKK can be recruited through an interaction with PKC family 
members while in TNFR1 signaling, IKK may be recruited to the receptor 
complex through the RIP1 kinase. The key remaining questions are to address the 
mechanisms by which TRAF proteins contribute to IKK activation, particularly in 
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conjunction with RIP proteins, and their contributions to NF-κB pathways in 
which their role has not yet been definitively established. 
 
 
 
 
Figure 3: Schematic representation of the members of the TRAF family. 
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TAK1/NIK—IKK Kinases 
 
Signaling to IKK downstream of RIPs and TRAFs depends on several kinases that 
have been implicated in NF-κB signaling pathways. In the case of canonical NF-
κB pathways this role is largely fulfilled by TAK1 (TGFβ-activated kinase-1) 
(Sato et al., 2005; Shim et al., 2005). In noncanonical pathways NIK is instead 
required for IKKα activation and p100 phosphorylation (Senftleben et al., 2001; 
Xiao et al., 2001). Whether NIK and TAK1 function analogously to one another, 
that is as putative IKK kinases (IKK-Ks), is a matter of some debate. Despite the 
clear requirement for TAK1 in multiple signaling pathways to IKK, the 
mechanism of action of TAK1 in signaling to NF-κB remains unclear. First, 
genetic ablation of TAK1 reveals variable NF-κB activation deficiencies in 
different canonical signaling pathways. TNFR1 signaling to NF-κB appears 
completely abolished, while the effect on antigen receptor signaling is more 
controversial (Liu et al., 2006; Sato et al., 2005; Wan et al., 2006). Second, 
whether TAK1 directly serves as an IKK-K, or mediates activation through an 
intermediary kinase, MEKK3 for example, is not yet clear (Blonska et al., 2005; 
Li et al., 2006a). Third, even though the pathways triggered by LTβR lead to IKK 
through many of the same signaling intermediates, this pathway does not depend 
on TAK1 (Shim et al., 2005). Instead it seems that TAK1 generally functions in 
pathways that also require RIP for the activation of IKK. Indeed, RIP may be 
responsible for the recruitment of TAK1 (Blonska et al., 2005). TAK1 has been 
implicated in both antigen receptor and NOD signaling pathways, neither of 
which has yet been shown conclusively to depend on TRAF proteins, although 
there are indications that this is likely to be the case (Abbott et al., 2007; 
Hasegawa et al., 2007; Sun et al., 2004). Alternatively, it may be that some 
pathways that signal independently of RIPs, which to date includes mainly 
noncanonical pathways, may activate IKK without TAK1. Conversely, NIK can 
activate the noncanonical pathway in the absence of RIP proteins. NIK directly 
phosphorylates and activates IKKα and this model is supported by analyses of 
NIK−/− and aly/aly mice, which bear an inactivating point mutation in the NIK 
kinase (Hacker and Karin, 2006). Regulation of NIK is regulated by the combined 
action of TRAF proteins, as discussed above. In addition to TRAF3, cIAP1 and 
cIAP2 have been implicated as E3 ligases responsible for regulating constitutive 
NIK levels (Petersen et al., 2007; Varfolomeev et al., 2007; Vince et al., 2007). 
Degradation of cIAP downstream of noncanonical stimuli may function, like 
degradation of TRAF3, in leading to the accumulation of NIK and IKKα 
activation (Varfolomeev et al., 2007). However, the mechanism of cIAP 
regulation following receptor ligation needs to be further characterized. 
In summary, a few common signaling components mediate activation of IKK 
under most circumstances. In the noncanonical pathway, TRAF and NIK are 
sufficient to activate IKKα in a NEMO-independent manner. However, the 
canonical pathway appears more complex. Generally canonical signaling relies 
on both TRAF and RIP proteins, as well as the kinase TAK1, although in certain 
pathways other proteins, e.g., IRAK1, may function analogously to RIP. It seems 
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that the key to this difference is likely to lie in binding of RIP, or analogous 
proteins, to NEMO, as both of these components may be universally 
required for canonical NF-κB activation. Whether this interaction allows TAK1 or 
another kinase to phosphorylate IKK or promotes IKK transautophosphorylation 
remains a matter of continuing debate. If there is no IKK-K in canonical 
pathways, however, then the exact function of TAK1 in IKK activation remains to 
be discovered. 
 
 
 
Organization and Activation of the IKK Complex 
 
Although exceptions have been reported, it is generally accepted that activation of 
NF-κB requires activation of either IKKα or IKKβ. It therefore follows that 
understanding the regulation of IKK activity is central to understanding the 
activation of NF-κB. Despite the significance of IKK, major gaps remain in our 
knowledge of the biochemistry of the IKK complex. However, several recent 
advances suggest that the field is on the verge of significant breakthrough into 
understanding the mechanism of IKK activation. The IκB kinase was first purified 
as a basally active, highmolecular-weight complex capable of phosphorylating 
serines 32 and 36 of IκBα (Chen et al., 1996). A stimulus-dependent kinase 
activity was subsequently identified by several groups and found to be composed 
of the two catalytic kinase subunits, IKKα (IKK1) and IKKβ (IKK2), and a 
regulatory subunit NEMO (IKKγ) (DiDonato et al., 1997; Mercurio et al., 1997; 
Rothwarf et al., 1998; Woronicz et al., 1997; Yamaoka et al., 1998; Zandi et al., 
1997; Regnier et al., 1997). IKKα and IKKβ, along with IKKi (IKKε) and TBK1, 
comprise the IKK family of proteins. IKKα and IKKβ share 52% overall sequence 
identity, with a greater degree of similarity in the catalytic domain (65%). NEMO 
is a 48 kDa protein that is not related to IKKα and IKKβ and contains a C-
terminal Zn finger-like domain, a leucine zipper, and N-terminal and C-terminal 
coiled-coil domains (Figure 2). Targeted disruption of each of the IKK genes as 
well as transgenic and conditional knockout animals have been generated and 
extensively analyzed and reviewed recently (Gerondakis et al., 2006; Pasparakis 
et al., 2006). Initially the similarity between the IKKβ knockout and p65 knockout 
phenotypes argued for a central role for IKKβ in activation of p65 dimers via 
IκBα phosphorylation. Mice deficient in IKKα survive embryonic development 
but die perinatally due to multiple morphological defects, in particular aborted 
epidermal and skeletal development. 
While initially it appeared that IKKα was dispensable for classical NF-κB 
activation, subsequent reports revealed the requirement for IKKα in multiple 
noncanonical NF-κB signaling pathways and perhaps some canonical signaling 
pathways as well (Solt et al., 2007; Takaesu et al., 2003). Furthermore, as 
discussed below, while not required for IκBα degradation in all pathways, IKKα 
likely plays an important role in NF-κB dependent gene expression in canonical 
signaling pathways. NEMO is required for signaling in all canonical NF-κB 
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pathways and NEMO-deficient mice also die embryonically of massive 
hepatocyte apoptosis. NEMO-deficient cells exhibit a more severe and broader 
loss of NF-κB activation than do IKKβ knockout cells, demonstrating that some 
canonical pathways are intact in the absence of IKKβ (Schmidt-Supprian et al., 
2000; Solt et al., 2007). Therefore, it is more appropriate to categorize NF-κB 
pathways as canonical or noncanonical based on the requirement for NEMO or on 
the specific IκB protein that is phosphorylated and degraded/processed, e.g., IκBα, 
IκBβ, and IκBε for canonical and p100 for noncanonical, rather than on the 
requirement for IKKα or IKKβ. 
 
 
 
B cell and NF-B 
 
BAFF-R-dependent activation of the alternative NF-κB pathway plays an 
essential role in mature B cell survival. Mutations leading to overexpression of 
NIK and deletion of the TRAF3 gene are implicated in human multiple myeloma. 
NIK controls alternative NF-κB signaling by increasing the protein levels of its 
negative regulator TRAF3 in a dose-dependent fashion. This mechanism keeps 
NIK protein levels below detection, even when they cause B cell hyperplasia, so 
that contributions of NIK to B cell pathologies can easily be overlooked. B cells 
are central players in adaptive immune responses and immunity, mainly through 
their ability to differentiate into antibody-producing plasma cells and long-lived 
memory B cells upon antigen-encounter. Their survival and function critically 
depend on extracellular cues, which upon recognition by cell-surface receptors 
induce defined gene expression programs via activation of specific signal 
transduction cascades and transcription factors. Deregulation of these signaling 
pathways can lead to autoimmunity and lymphomagenesis. The NF-B signal 
transduction cascade has emerged as a critical players in all of these process 
(Courtois G. et al. 2006; Hayden M.S. et al., 2006; Karin M. et al., 2002). In 
mature resting B cells, both pathways of NF-κB activation are induced and their 
generation and survival depends on both, demonstrated by gene disruption in the 
mouse at the level of transcription factors and signaling proteins (Sen R., 2006; 
Siebenlist U., 2005). It has been shown that the binding of B cell-activating factor 
of the TNF family (BAFF or BLyS) to BAFF-R (BR3), one of its three receptors, 
the others being transmembrane activator, calcium modulator, and cyclophilin 
ligand interactor (TACI), and B cell maturation antigen (BCMA) is required and 
sufficient to sustain the p100 processing needed for B cell survival (Siebenlist U., 
2005). The main role of the alternative NF-κB branch in mature B cells appears to 
be the transmission of a survival signal elicited by BAFF, whose limited 
availability regulates the size of the peripheral B cell pool. Recent B cell-specific 
ablation studies of tumor necrosis factor receptor-associated factors (TRAFs) 
TRAF2 (Grech A.P. et al. 2004) and TRAF3 (Xie p. et al., 2007; Gardam S. et al., 
2008) in mice have revealed striking phenotypic similarities to BAFF-transgenic 
mice, such as a pronounced B cell hyperplasia due to enhanced cell survival. On a 
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molecular level, lack of TRAF2 or TRAF3 prominently induces robust p100 
processing, independent of the presence of BAFF (Grech A.P. et al. 2004; Xie p. 
et al., 2007; Gardam S. et al., 2008). The most straightforward explanation for this 
phenomenon is that the absence of TRAF2 or TRAF3 increases the protein 
concentration of NIK, as seen in TRAF3-deficient fibroblasts and transformed B 
cells (He J.Q. et al., 2007; He J.Q. et al., 2006; Liao G. et al., 2006), and 
suggested by the stabilization of NIK achieved through the removal of its TRAF3-
binding domain (T3BD) (Liao G. et al., 2006). However, elevated amounts of 
NIK protein could not be detected in primary B cells lacking TRAF2 or TRAF3. 
The alternative pathway has been implicated in hematopoietic malignancies 
through chromosomal abnormalities leading to the production of truncated p100 
proteins with diminished NF-κB-inhibitory ability. Recently, two independent 
studies uncovered genetic aberrations affecting components of NF-κB activation, 
mostly assigned to the alternative branch, in human multiple myeloma cell lines 
(HMCL) and in 9% (Annunziata C.M. et al., 2007) or 17% (Keats J.J. et al., 2007) 
of patient cohorts with multiple myeloma (MM). These aberrations led to the 
absence of negative regulators of NF-κB, such as TRAF3, TRAF2, cellular 
inhibitor of apoptosis proteins 1 and 2 (c-IAP1/2), and cylindromatosis protein 
(CYLD) or to overexpression of NIK. Collectively, these studies indicate that 
deregulation of the TRAF3-NIK axis might play an important role in 
lymphomagenesis.  
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Fig.4: NF-kB signaling in Macrophage and B Cells 
 
 
TRAF1 
 
TRAF1 is unique among TRAFs because it lacks the “really interesting new gene” 
(RING) domain found near the NH2- terminal regions of TRAF2-6. Deletion of 
the RING domain, which contains a Zn2+-binding fold, from TRAF2, TRAF5, or 
TRAF6, revealed that the RING domain is critical for the activation of NF-κB or 
Jun NH2-terminal kinase (JNK) (Bradley J.R. et al., 2001). Moreover, RING-
deleted (ΔRING) mutants of these TRAFs typically inhibit signal transduction by 
members of the TNFR family. Given the absence of a RING domain in TRAF1, it 
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may not be surprising that a recent paper from Tsitsikov and co-workers has 
provided in vivo evidence of a negative regulatory role for TRAF1 in mice by 
demonstrating enhanced TNF signaling in TRAF1-deficient mice (Tsitsikov E.N. 
et al., 2001). However, when compared with other observations concerning 
TRAF1, one wonders whether there might be more to the story of this unique 
TRAF family member. 
The expression of TRAF1 is the most restricted among TRAFs; TRAF1 is found 
almost exclusively in activated lymphocytes, dendritic cells, and certain epithelia 
(Zapata J.M. et al., 2000). TRAF1 has been reported to associate directly or 
indirectly with multiple TNFR family members. Though results are sometimes 
based on overexpression experiments, TRAF1 reportedly also binds several 
intracellular proteins, including adaptor proteins such as TNFR-associated death 
domain protein (TRADD), TRAF-associated and NF-κB activator (TANK, also 
known as I-TRAF), and TRAF-interacting protein (TRIP); protein kinases such as 
NF-κB-inducing kinase (NIK), receptor-interacting protein (RIP) and RIP2 
(Cardiak); the NF-κB inhibitory protein A20; and the apoptosis-suppressors 
inhibitor of apoptosis 1 (cIAP1), cIAP2, and FADD-like interleukin-1β converting 
enzyme (FLICE)-like inhibitory protein (FLIP). Additionally, TRAF1 forms 
heteromers with TRAF2. TRAF1 can also be recruited to the TNFR1 and TNFR2 
through its interaction with TRADD and TRAF2, respectively, where it is also 
found associated with cIAP1 and cIAP2. 
This plethora of interacting partners positions TRAF1 for multiple possible 
functions and suggests that absence of this protein should produce several defects 
in cytokine signal transduction networks. Surprisingly, however, Tsitsikov and 
coworkers find that TRAF1 knockout mice are phenotypically normal in 
appearance. TRAF1-/- mice have no apparent defects in development of either T 
cells or B cells, and have normal numbers of lymphocytes in peripheral lymphoid 
organs, unimpaired antibody responses to both T-dependent and T-independent 
antigens, and typical kinetics of lymphocyte deletion and expansion in response to 
superantigen. Only the inguinal lymph nodes of TRAF1-deficient mice showed 
significant differences compared to wild-type littermates, having a larger number 
of lymphocytes and an increased T/B cell ratio. These results stand in sharp 
contrast to the those of gene knockouts for TRAF2, TRAF3, TRAF4, and TRAF6; 
striking developmental defects in these mice are evident. 
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AIM OF THE STUDY 
 
BAFF-Receptor dependent activation of the alternative NF-B pathway plays an 
essential role in mature B cells survival. Mutations leading to overexpression of 
NIK and deletion of the TRAF3 gene are implicated in human lymphoma and 
myeloma. This overexpression of NIK leads to an uncontrolled activation of NF-
B2 that seems to be the cause of tumoral transformation. In the same cells the 
expression of TRAF1 is upregulated. For this reasons the aims of our study is to 
correlate this two events and to clarify some mechanisms of function of NF-B2. 
  
25 
 
MATERIALS AND METHODS 
 
1 -  Cell Culture and Biological Reagents  
 
HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium 
(Invitrogen) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 
100 mg/ml streptomycin, and 1% glutamine. Lymphocytes B cells U266 
(myeloma) were maintained in RPMI medium (Invitrogen) supplemented with 
10% fetal bovine serum, 100 units/ml penicillin, 100 mg/ml streptomycin, and 1% 
glutamine. Antibodies used for this study were: FLAG epitope (Sigma), HA 
epitope, TRAF1 polyclonal, GST, p52 polyclonal, Actin and Tubulin (Santa Cruz 
Biotechnologies), Anti-NIK polyclonal antibodies were generated in rabbits, by 
using a recombinant peptide. Human BAFF (Peprotech Inc.) was used at 100 
ng/ml.  
Human TRAF1, Baff receptor, NIK, TRAF3 and p100/p52 was amplified by PCR 
from human PBL cDNA library (BD clontech)  and cloned into pcDNA3-FLAG, 
–HA and pGEX2T vectors (Invitrogen) for expression in mammalian cells. All 
deletion mutant were prepared by conventional PCR and cloned into pcDNA3-
FLAG, –HA. 
 
 
2 - In Vitro Translation and GST Pull-down Assays 
 
In vitro transcription and translation were carried out with 1 g of FLAG-TRAF1 
and FLAG-TRAF3 constructs according to the TNT Quick Coupled 
Transcription/Translation System protocol (Promega). GST-BAFF receptor fusion 
protein was produced and purified as described (33). GST pull-down assays were 
performed by incubating an aliquot of GST-BAFF receptor bound to glutathione-
Sepharose beads (Amersham Biosciences) together with 10, 20 e 30 l of in vitro 
translated FLAG-TRAF1 and 10l of FLAG-TRAF3  protein in phosphate-
buffered saline, 1% Triton X-100 buffer (including Complete Protease Inhibitor 
mixture (Roche)) for 2 h at 4 °C. Beads were then washed five times with the 
same buffer, resuspended in Laemmli buffer, and run on a SDS-polyacrylamide 
gel before autoradiography. 
 
 
3 - Transfection, Immunoprecipitation, and Luciferase Assay  
 
LipofectAMINE-mediated transfections were performed according to the 
manufacturer’s instructions (Invitrogen). All transfections included supplemental 
empty vector to ensure that the total amount of transfected DNA was kept 
constant in each dish culture. 
For immunoprecipitation of transfected proteins, HEK293 cells (3 x 10
6
) were 
transiently transfected and 24 h after transfection cells were lysed in Triton X-100 
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lysis buffer (20 mM Hepes pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-
100, and Complete Protease Inhibitor mixture). After an additional 15 min on ice, 
cell extracts were centrifuged for 10 min at 14,000xg at 4 °C and supernatants 
were incubated for 3 h at 4 °C with anti-FLAG antibodies bound to agarose beads 
(M2, Sigma). The immunoprecipitates were washed five times with Triton X-100 
lysis buffer and subjected to SDS-PAGE.  
For luciferase assay, HEK293 cells (3x10
5
) were seeded in 6-well plates. After 12 
h cells were transfected with 0.5 g of Ig-B-luciferase reporter plasmid and 
various combinations of expression plasmids. 24 h after transfection cells extracts 
were prepared and reporter gene activity was determined via the luciferase assay 
system (Promega). Expression of the pRSV--galactosidase vector (0.25 g) was 
used to normalize transfection efficiencies. 
 
 
4 -  In Vivo Ubiquitination and De-ubiquitination Assays 
 
HEK293 cells (3 x 10
6
) were co-transfected with expression vectors containing 
HA-epitope-tagged ubiquitin (1 g) and various combinations of expression 
plasmids. 24 h after transfection, cell lysates were prepared as above and analyzed 
for polyubiquitination of TRAF3 either by Western blot anti-TRAF3 (FLAG) on 
total extracts or by immunoprecipitating FLAG-TRAF3 with anti-FLAG beads 
followed by Western blot anti-HA-ubiquitin. 
 
 
5 -  TRAF1  Short hairpin RNA (shRNA) Expression Vectors    
 
To knockdown TRAF1 expression in Myeloma B cells L1236, we have used 
“SHVRS MISSION shRNA Lentiviral Particles” of Sigma. shRNA Lentiviral 
Particles are transduction -ready viral particles for gene silencing in mammalian 
cells (human or mouse) including both dividing, non-dividing, and primary cell 
types. After transduction, stable cell lines expressing the shRNA was selected 
with puromycin. 
MISSION™ TRC shRNA Target Set 
TRCN0000056883:CCGGGCAGTCTCAATGGGTCAGAAACTCGAGTTTCTGACCCATTGA
GACTGCTTTTTG 
TRCN0000056884:CCGGGCCTTCTACACTGCCAAGTATCTCGAGATACTTGGCAGTGTA
GAAGGCTTTTTG 
TRCN0000056885:CCGGCGTGTGTTTGAGAACATTGTTCTCGAGAACAATGTTCTCAAA
CACACGTTTTTG 
TRCN0000056886:CCGGGATGAGAATGAGTTTCCCTTTCTCGAGAAAGGGAAACTCATT
CTCATCTTTTTG 
TRCN0000056887:CCGGCATTGTGGAGACCAGCACTTACTCGAGTAAGTGCTGGTCTCC
ACAATGTTTTTG 
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6  -   RNA extraction and RT–PCR assays 
 
The U266 cells lines were stimulated with Baff Ligand (Peprotech) for the hours 
indicated. Total RNA (1 μg) isolated from U266 cells lines by the Chomczynski 
and Sacchi method (Chomczynski and Sacchi 1987). After checking the integrity 
of RNA by electrophoresis on agarose gel, an aliquot of total RNA was incubated 
for 15 min at 37°C with 20 U of RNAse-free DNAse I (Promega, Madison, WI) to 
digest contaminating genomic DNA. 
RT-PCR experiments were performed in accordance to standard methods (Innis at 
al. 1990). 0,5 g of  cDNA were amplified in 50 l of PCR buffer (Promega) 
containing 15 pmol of TRAF1 specific forward and reverse primers (see below). 
After a first step of denaturation for 2 min at 95°C, 25 or 35 cycles of cDNA 
amplification from cells lines extracts were performed as follows: 30 sec at 95°C, 
30 sec at 55°C and 30 sec at 72°C with a final extension of 5 min at 72°C. The 
last 20 cycles of amplification were carried out adding 15 pmol of human GAPDH 
forward and reverse specific primers to the PCR mixture. The following TRAF1 
primers were used: forward 5’-cta ccg ggc acc ctg ctc cg-3’ and reverse 5’-gca ttg 
tgg aga cca gca ctt ag-3’. The cDNA concentrations were normalized by GAPDH 
mRNA content. 
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RESULTS AND DISCUSSION 
 
Identification of TRAF1 as a specific BAFF-R-interacting protein 
 
The intracellular signaling pathway mediated by BAFF-R is only partially known.
 
Similar to other members of the TNFR family, BAFF-R does not have
 
intrinsic 
enzymatic activity, and is believed to transduce signals through
 
physical 
interaction with downstream signaling proteins. Because TRAF proteins are 
involved in signaling by many members
 
of the TNFR family, we decided to 
investigate a potential
 
role for TRAF1 in BAFF-R signaling. To determine 
whether TRAF1
 
is associated with cytosolic domain of BAFF-R in mammalian 
cells, expression plasmids encoding the intarcellular domain of BAFF Receptor, 
and Flag-tagged TRAF1
 
were transfected into 293 cells. Coimmunoprecipitation 
experiments
 
indicated that BAFF-R interacted with TRAF1 (Fig. 5A). In order to 
confirm the interaction and to demonstrate a direct interaction between BAFF 
Receptor and TRAF1, we performed GST-pull-down assay, recombinant protein
 
GST-BAFF-R was purified in E. Coli (DH5 and Flag-tagged TRAF1 and 
TRAF3
 
were produced with Reticolcytes Trascription/Traslation System. The 
interaction between BAFF Receptor and TRAF3 was used as positive control of 
interaction. As shown in figure 5B TRAF1 was directly binding cytoplasmic 
domain of BAFF Receptor. This experiment also suggests that binding of TRAF1 
and TRAF3 to the receptor involved different domains of the receptor. In fact, 
increasing amount of TRAF1 was not affecting the binding of TRAF3 to the 
receptor. 
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Figure 5: BAFF-R interacts with TRAF1 in 293 cells. A, 293 cells were transfected with 
expression plasmids for C-terminal HA-tagged BAFF-R and the indicated Flag-tagged TRAF1 
protein. Cell lysates were immunoprecipitated with anti-Flag Ab. The immunoprecipitates were 
analyzed by Western blot with anti-HA (upper panel). Expression of BAFF-R and TRAF1 
proteins was confirmed by Western blots with anti-HA (middle panel) and anti-Flag (lower panel) 
Abs, respectively. B, Confirmation of interaction with pull-down. Purified GST-BAFF Receptor 
was incubated with FLAG-TRAF1 or TRAF3 and immunoprecipitated with Glutation Sepharose 
4B and analyzed by W.B. with anti-Flag (upper panel) and with anti-GST (lower panel). 
 
 
Domain mapping of the interaction between BAFF Receptor and TRAF1 
 
TRAF proteins interact with members of the TNFR family through their
 
TRAF 
domains. To determine the regions of
 
TRAF1 that are required for interaction with 
BAFF-R, we generated
 
a series of C-terminal HA-tagged deletion mutants of the 
TRAF1
 
(Fig. 6A). Transient transfection of 293 cells and coimmunoprecipitation
 
experiments suggest that the amino acid between 300-350 are required for 
interaction with BAFF-R (Fig. 6B). 
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Figure 6. Mapping of TRAF1 interaction with BAFF-R. A, A schematic presentation of the 
TRAF1 deletion mutants and their interaction with BAFF-R. TD, TRAF Domain; ZF, Zinc Finger. 
B, Coimmunoprecipitation between BAFF-R and TRAF1 mutants. 293 cells were transfected with 
31 
 
expression plasmids for HA-tagged BAFF-R and the indicated C-terminal Flag-tagged TRAF1 
mutants. Cell lysates were immunoprecipitated with anti-Flag Ab and the immunoprecipitates 
were analyzed by Western blot with anti-HA Ab (lower  panel). Expression of TRAF1 mutants 
and BAFF-R was confirmed by Western blots with anti-Flag (upper  panel) and anti-HA (middle  
panel) Abs, respectively. 
 
 
TRAF1 positively regulates NF-B activation by inhibiting TRAF3 protein 
expression 
 
TRAF3 is a negative regulator of p100 processing. To determine  whether TRAF1 
is involved in degradation of NIK by TRAF3, we transfected, in 293 cells, NIK, 
HA-tagged TRAF3 and increasing amount of HA-TRAF1. The cell lysates were 
analyzed by Western blot with anti-HA and anti-NIK Abs. As shown in figure 7A, 
ectopic expression of TRAF3 decreased the level of NIK and blocks processing of 
p100. However, in the presence of increasing amount of TRAF1, TRAF3 is 
decreased, the level of NIK is stabilized and processing of p100 is restored. The 
positive effect played by TRAF1 on p100 processing was farther confirmed by 
evaluating the effect of TRAF1 in the activity of an alternative pathway specific 
B reporter (Bonizzi at al. 2004 EMBO J.). As shown in figure 7B, the NIK 
dependent alternative pathway activation, was blocked by TRAF3 and restored in 
the presence of TRAF1. 
These results strongly suggest that TRAF1 is a positive regulator of the alternative 
pathway, interfering with the TRAF3-mediated NIK degradation.  
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Figure 7. TRAF1 induce decrease of TRAF3 level and consequently a stabilization of NIK and an 
increase of p100 processing. A, 293 cells were transfected with expression plasmids for NIK, HA-
TRAF1, HA-TRAF3 and FLAG-p100. Cell lysates  were analyzed by Western blot with anti-NIK 
(upper panel), anti-HA and anti-FLAG (middle panel) Abs. The Western blot anti-Tubulin was 
used as a control for total proteins expression. B. TRAF1 induce activation of alternative pathway 
of NF-B. Relative reporter activity was evaluated in HEK-293T cells co-transfected with the Ig-
B-luciferase alternative and mutated plasmid and the indicated expression vectors. Values shown 
in arbitrary units represent the mean ± S.D. of three experiments done in triplicate, normalized for 
-galactosidase expression of a co-transfected pRSV--galactosidase plasmid. 
 
 
Induction of TRAF1 upon BAFF ligand stimulation in myeloma B cells 
 
In order to understand if expression of TRAF1 was inducible after BAFF 
stimulation U266 cells were stimulated with BAFF, and the expression of TRAF1 
was evaluated by semi-quantitative PCR. As shown in figure 8A BAFF treatment 
caused a marked increase in TRAF1 mRNA expression. The increased expression 
of TRAF1 correlated with p100 processing (Fig. 8B).  
 
 
i  .  i    
i r  f  i . ,   
, -   . 
(  l), ti   ti  
s    tr l  t t l t i  
f - . l ti  t  ti  
-l if r  lt ti    
i  r itr r  it  t t    
- l t i  i    
 
 
ti  f  
 
  t  
ti l ti   
 l t   
   
   
 
33 
 
 
 
 
 
 
Figure 8: Induction of TRAF1 upon BAFF ligand stimulation in myeloma B cells. A. U266 cells 
were stimulated with 100 ng/ml of BAFF ligand for the indicated hours. Then it was extracted 
mRNA, converted in cDNA by RT-PCR and run on 1% agarose elettrophoresis gel. The GAPDH 
(housekeeping gene) cDNA was used for a control of total amount of cDNA present in the various 
preparations. B. An aliquot of the same cells used for the extraction of mRNA was lysated and 
analyzed by W.B. anti-TRAF1 (upper panel) and anti-p52 (middle panels) Abs. The Western blot 
anti-Actin was used as a control for total proteins expression. 
 
 
TRAF1 down-regulation decreases p100 processing and affects B cell survival 
 
To further demonstrate the positive role played by TRAF1 in regulating p100 
processing, we decreased its expression in the lymphoma B cell line L1236 by 
shRNA. We utilized 3 different shRNA constructs named Cl1, Cl3 and Cl5 and 1 
scramble shRNA as control. Cells were transduced with two different amount of 
lentiviral particles carrying the shRNA. As shown in figure 9, all the shRNA used 
decreased the expression of TRAF1, albeit at different level. As expected the 
decreased in TRAF1 expression caused a decrease in p100 processing. 
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Figure 9: The interference of TRAF1 induces the decrease of p100 processing. L1236 cells were 
infected with Lentiviruses leads shTRAF1 interference constructs Cl1, Cl3, Cl5 and Sc. 
(scramble)in two different amounts A and B. Then cells were treated with 5 g/ml of puromycin 
for kill untransduced cells. The survived cells were expanded and then subjected to a W.B. anti 
TRAF1(upper panel), p100 and p52 (middle panel). The Western blot anti-Actin was used as a 
control for total proteins expression. 
 
 
The constitutive activation of the alternative pathway is important for B cell 
survival. Then we investigated the survival of the B lymphoma cell line L1236 
transduced with shRNA for TRAF1. As shown in figure 10 the survival of the B 
cell line L1236 is decreased in absence of TRAF1. 
Taken together these results demonsytrated that TRAF1 is a positive regulator of 
p100 processing, and plays a role in controlling survival of lymphoma cells. 
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Figure 10: TRAF1 down-regulation affects B cell survival. The L1236 were transduced with a 
lentivirus expressing the TRAF1 shRNA. Live cells were enumerated by MTT for the indicated 
number of days. 
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DISCUSSION 
 
In the present paper we identify TRAF1 as a Baff-receptor interacting protein, and 
present evidence for  a role of TRAF1 as a positive regulator of the NF-B 
alternative pathway. Activation of the NF-B alternative pathway is essential for 
the organization of the secondary lymphoid tissue, and deregulation of this 
pathway has been detected in multiple myeloma cell lines and patients. These 
mutations affect both negative regulator (TRAF2, TRAF3, c-IAP1/2), and positive 
regulator (NIK) of the pathway.  
In the current model of activation of the alternative pathway, TRAF3 
constitutively binds to and ubiquitinates the protein kinase NIK. After receptor 
engagement, TRAF3 is degraded, the level of NIK increases, and then NIK may 
phosphorylate  IKK to activate the complex. However, how engagement of the 
receptors that control B cell survival and development (such as CD40 and BAFF-
R) regulates this process is currently unknown. Protein synthesis is required to 
activate the pathway, indeed p100 processing take place few hours after receptor 
engagement and is blocked by protein synthesis inhibitor. In our experimental 
model, TRAF1 is induced by BAFF-R triggering and its induction correlates with 
the increased p100 processing. In addition, we present evidence that the simple 
overexpression of TRAF1 decreases the level of TRAF3 and stabilizes NIK, thus 
mimicking receptor triggering. How TRAF1 interfere with TRAF3 function? A 
possible explanation might be that TRAF1 compete with TRAF3 for binding to 
the receptor. However, our data suggest that this is not the case, as increasing 
amount of TRAF1 does not displace TRAF3 from binding to the receptor ( Fig 12 
and data not shown). Another possibility is that TRAF1 displaces TRAF3 from 
NIK, thus preventing its ubiquitination and degradation. We are currently 
exploiting this possibility also if, at least in transfected cells, binding of TRAF3 to 
NIK is not affected by TRAF1 overexpression. There is another intriguing 
possibility: in the presence of TRAF1, TRAF3 became substrate for another 
ubiquitin ligase activity, leading to TRAF3 degradation, and NIK stabilization. 
Indeed, very recently, it has been recently proposed by Karin and colleagues, and 
by Chen and colleagues that TRAF3 degradation is mediated by a multimeric 
complex containg c-IAP1 and c-IAP2. This result suggest that TRAF1 may 
function to bridge interaction between IAPs and TRAF3. We are currently 
investigating if TRAF1 is part of this complex. 
The present work also demonstrate that blocking expression of TRAF1 by shRNA 
in myeloma cells, blocks processing of p100 thereby affecting survival of 
myeloma cells. Elegant work recently found that a subgroup of multiple myeloma 
cells expresses elevated alternative pathway NF-B activity, owing to 
amplification of NIK or mutation in TRAF3.  This result confirm the central role 
played by the alternative NF-kB pathway in lymphocyte survival, and suggest that 
amplification of TRAF1 may also be responsible for a subgroup of multiple 
myeloma. Indeed, TRAF1 mRNA and protein levels are typically increased in B 
cell malignancies, including non-Hodgkin lymphomas, chronic lymphocytic 
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leukemias, as well as the Reed-Stemberg cells of Hodgkin disease. On the other 
hand, although T cells from TRAF1-null mice exhibited enhanced proliferation in 
vitro, their B cells have normal proliferation  rates upon IgM or CD40 binding. In 
addition, TRAF1 transgenic mice that overexpress this protein in T cells, have 
normal basal and CD3-stimulated proliferation compared to control littermates, 
suggesting that overproduction of TRAF1 does not alter CD3-mediated T cell 
proliferation. However, in the same experimental setting, the TCR mediated-
apoptosis is reduced. How do we reconcile these disparate observation? It is very 
possible that the difference in cell context may provide an explanation. However, 
it is possible that  in vivo the simple overexpression of TRAF1 is not sufficient to 
sustain proliferation and/or resistance to apoptosis in normal B cells. Perhaps, 
mating of TRAF1 transgenic mice that overexpress this protein in B cells, with 
oncogene-expressing transgenic mice that develop B cell malignancies will shed 
some light on these questions.  
Collectively, our results in addition to identify TRAF1  as a positive regulator of 
the alternative NF-kB activation pathway, identify TRAF1 as a potential target for 
treatment of myeloma. 
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ABIN-1 Binds to NEMO/IKK and Co-operates with
A20 in Inhibiting NF-B*□S
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Nuclear factor B (NF-B) plays a pivotal role in inflammation,
immunity, stress responses, and protection from apoptosis. Canon-
ical activation of NF-B is dependent on the phosphorylation of the
inhibitory subunit IB that is mediated by a multimeric, high
molecular weight complex, called IB kinase (IKK) complex. This is
composed of two catalytic subunits, IKK and IKK, and a regula-
tory subunit, NEMO/IKK. The latter protein is essential for the
activation of IKKs and NF-B, but its mechanism of action is not
well understood. Here we identified ABIN-1 (A20 binding inhibitor
of NF-B) as a NEMO/IKK-interacting protein. ABIN-1 has been
previously identified as anA20-binding protein and it has been pro-
posed to mediate the NF-B inhibiting effects of A20. We find that
bothABIN-1 andA20 inhibit NF-B at the level of the IKK complex
and that A20 inhibits activation of NF-B by de-ubiquitination of
NEMO/IKK. Importantly, small interfering RNA targeting
ABIN-1 abrogates A20-dependent de-ubiquitination of NEMO/
IKK and RNA interference of A20 impairs the ability of ABIN-1 to
inhibit NF-B activation. Altogether our data indicate that ABIN-1
physically links A20 to NEMO/IKK and facilitates A20-mediated
de-ubiquitination of NEMO/IKK, thus resulting in inhibition of
NF-B.
NF-B is a ubiquitously expressed family of transcription factors that
controls the expression of numerous genes involved in immune and
inflammatory responses (1). NF-B also plays an important role during
cellular stress responses, due to its anti-apoptotic and proliferation-
promoting functions (2). Aberrant activation of NF-B is a major hall-
mark of several inflammatory diseases such as arthritis (3, 4), and a
variety of human cancers (5, 6). In resting cells, NF-B is sequestered in
the cytoplasm in an inactive formbymembers of the inhibitory family of
IB proteins (1). Various stimuli including pathogens, pathogen-related
factors, and cytokines lead to phosphorylation of the inhibitory subunit
IB on specific serine residues (Ser32 and Ser36) (7) catalyzed by two
IB kinases (IKKs),3 namely IKK and IKK (8–12). This step marks
the IB protein for ubiquitination and subsequent degradation through
a proteasome-dependent pathway (1). The active NF-B is then free for
translocation to the nucleus, where it binds the B sequences present in
the promoters of responsive genes.
IKK and IKK reside in a larger kinase complex (700–900 kDa),
called the IB kinase complex (IKK complex), that also contains the
essential regulatory subunit NEMO (also known as IKK) (13, 14).
Genetic studies suggest that NEMO/IKK is absolutely required for the
activation of IKKs and NF-B in response to different stimuli (13, 15).
NEMO/IKK contains several coiled-coil domains, a leucine zipper,
and a C-terminal zinc finger domain. These motifs are required for the
correct assembly of the IKK complex (13) and recruitment of upstream
signaling mediators (16). Numerous proteins have been demonstrated
to interact with NEMO/IKK, as the kinase RIP and the inhibitor of
NF-BA20 (17), the viral trans-activator TAX (18–20), and the adaptor
proteins CIKS/Act-1, TANK, and CARMA (21–23). Therefore,
NEMO/IKK represents the point where most NF-B signaling path-
ways converge. Despite this information, themolecularmechanism reg-
ulating IKK complex function is not fully understood.
Ubiquitin conjugation has been most prominently associated with
protein degradation through a proteasome-dependent pathway, but it is
becoming increasingly evident that ubiquitination plays a key role in the
signal transduction pathway leading to activation of NF-B (24, 25).
Recent reports show that lysine 63-linked ubiquitination of NEMO/
IKK is an important step for the activation of IKKs and NF-B follow-
ing various stimuli, such as TNF, lipopolysaccharide, and antigen recep-
tor (26–28). In contrast, the tumor suppressor CYLD is reported as a
negative regulator of NF-B by specific de-ubiquitination of NF-B sig-
naling molecules, such as TRAF2, TRAF6, and NEMO/IKK (29). Also
A20 functions as an inhibitor of the NF-B pathway by removing Lys63-
linked ubiquitin chains from RIP, an essential mediator of the proximal
TNF-Receptor-1 signaling complex. Then A20 targets RIP for Lys48-
linked polyubiquitination and proteasomal degradation (30). Further-
more, A20 terminates Toll-like receptor-induced NF-B signaling, by
cleaving ubiquitin chains from TRAF6 (27). The central role played by
A20 in terminatingNF-B activation is further demonstrated by the fact
thatA20/mice develop severe inflammation and cachexia, are hyper-
sensitive to both lipopolysaccharide and TNF, and die prematurely (27,
31). Here we used NEMO/IKK as bait in yeast two-hybrid screening,
and identified ABIN-1 (A20 binding inhibitor of NF-B) as a NEMO/
IKK-interacting protein.
EXPERIMENTAL PROCEDURES
Cell Culture and Biological Reagents—HEK293 cells were maintained
in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with
10% fetal calf serum, 100 units/ml penicillin, 100mg/ml streptomycin, and
1% glutamine.
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Anti-ABIN-1 polyclonal antibodies were generated in rabbits, by
using a recombinant peptide encompassing amino acids 380–636 of
human ABIN-1. Other antibodies used for this study were: FLAG
epitope (Sigma), A20 (BD Pharmingen), HA epitope, NEMO/IKK,
IKK, IB, and tubulin (Santa Cruz Biotechnologies). Human TNF-
(Peprotech Inc.) was used at 2,000 units/ml.
Human ABIN-1 was amplified by PCR from a human liver c-DNA
library (Clontech) and cloned into pcDNA3.1-HA, -FLAG, and -His
vectors (Invitrogen) for expression in mammalian cells. A20, TAX, and
ubiquitin expression vectors were gifts from G. Natoli, T. K. Jeang, and
G. Courtois, respectively. NEMO/IKK, IKK, CIKS, and TRAF2
expression vectorswerepreviouslydescribed (21, 32).All deletionmutants
were prepared by conventional PCR and cloned into pcDNA3.1-HA or
-FLAG vectors. Point mutants of A20 (C103S and D100A/C103S) were
generated by the QuikChange Site-directed Mutagenesis kit (Stratagene),
according to the manufacturer’s protocol.
Yeast Two-hybrid Screening—The cDNA encoding the N-terminal
part of mouse NEMO/IKK (amino acids 1–311) was cloned in-frame
into the GAL-4 DNA-binding domain vector pGBKT7 (Clontech). The
resulting plasmid pGBKT7-NEMO/IKK was used as bait in a yeast
two-hybrid screen of a human liver cDNA library (Clontech) in Saccha-
romyces cerevisiae strain AH109. The NEMO/IKK deletion mutants
for two-hybrid mapping were made by conventional PCR and cloned
into the pGBKT7 vector.
Gel Filtration of Cellular Extracts—Gel filtration procedures were
performed as previously described (42). Fractions were analyzed by
Western blotting for ABIN-1, NEMO/IKK, and IKK.
In Vitro Translation and GST Pull-down Assays—In vitro transcrip-
tion and translation were carried out with 1 g of ABIN-1 constructs
according to the TNT Quick Coupled Transcription/Translation Sys-
tem protocol (Promega) in the presence of [35S]methionine.
GST-NEMO/IKK fusion protein was produced and purified as
described (33). GST pull-down assays were performed by incubating
an aliquot of GST-NEMO/IKK bound to glutathione-Sepharose
beads (Amersham Biosciences) together with 10 l of in vitro trans-
lated ABIN-1 protein in phosphate-buffered saline, 1% Triton X-100
buffer (including Complete Protease Inhibitor mixture (Roche)) for
2 h at 4 °C. Beads were then washed five times with the same buffer,
resuspended in Laemmli buffer, and run on a SDS-polyacrylamide
gel before autoradiography.
Transfection, Immunoprecipitation, and Luciferase Assay— Lipo-
fectamine-mediated transfectionswere performed according to themanu-
facturer’s instructions (Invitrogen). All transfections included supple-
mental empty vector to ensure that the total amount of transfected
DNA was kept constant in each dish culture.
For immunoprecipitation of transfected proteins, HEK293 cells (3
106) were transiently transfected and 24 h after transfection cells were
lysed in Triton X-100 lysis buffer (20 mM Hepes, pH 7.4, 150 mM NaCl,
10% glycerol, 1% Triton X-100, and Complete Protease Inhibitor mix-
ture). After an additional 15 min on ice, cell extracts were centrifuged
for 10min at 14,000 g at 4 °C and supernatants were incubated for 4 h
at 4 °C with anti-FLAG antibodies bound to agarose beads (M2, Sigma).
The immunoprecipitates were washed five times with Triton X-100
lysis buffer and subjected to SDS-PAGE.
For luciferase assay, HEK293 cells (4  105) were seeded in 6-well
plates. After 12 h cells were transfected with 0.5 g of Ig-B-luciferase
reporter plasmid and various combinations of expression plasmids. 24 h
after transfection, cells were stimulated with TNF- for 3 h or left
untreated. Cell extracts were prepared and reporter gene activity was
determined via the luciferase assay system (Promega). Expression of the
pRSV--galactosidase vector (0.2 g) was used to normalize transfec-
tion efficiencies.
FIGURE 1. Mapping of the ABIN-1 interaction
domain onNEMO/IKK. A, mapping of the NEMO/
IKK-ABIN interaction by yeast two-hybrid experi-
ments. TheNEMO/IKK constructs are schematically
represented. The interaction of theNEMO/IKK con-
structs with the clone isolated by yeast two-hybrid
screening (ABIN 380–636) is indicated by the plus
sign. B, in vivo mapping of the NEMO/IKK-ABIN
interaction. HEK293 cells were transfected with
the indicated combinations of expression con-
structs encoding HA-ABIN and either FLAG-
NEMO/IKK or FLAG-NEMON91. Cell extracts
were analyzed by immunoblotting either directly
or after immunoprecipitation with anti-FLAG anti-
bodies.C, chromatographic distribution of endog-
enous ABIN-1, NEMO/IKK, and IKK. Cytoplasmic
extracts were prepared from HEK293 treated with
TNF for 120 min or left unstimulated, and sub-
jected to chromatography on a Superdex S-200
column. Fractions were analyzed by Western blot
(WB) by using the indicated antibodies. Molecular
weight markers are indicated at the top of the
figure.
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In Vivo Ubiquitination and De-ubiquitination Assays— HEK293 cells
(3  106) were co-transfected with expression vectors containing
epitope-tagged ubiquitin (1 mg) and NEMO/IKK (200 ng), plus
various constructs encoding A20 or ABIN-1 proteins. 24 h after
transfection, cell lysates were prepared as above and analyzed for
polyubiquitination of NEMO/IKK either by Western blot anti-
NEMO/IKK (-FLAG) on total extracts or by immunoprecipitating
FLAG-NEMO/IKK with anti-FLAG beads followed by Western
blot anti-HA-ubiquitin.
ABIN-1 Small Interfering RNA (siRNA) Expression Vectors—
To knockdown ABIN-1 expression, we designed double-stranded oli-
gonucleotides containing sequences derived from the human ABIN-1
open reading frame (nucleotides 1136–1156 and 1685–1705) in forward
and reverse orientations separated by a 7-base pair spacer region (caagaga)
to allow the formation of the hairpin structure in the expressed siRNAs;
ABINi-370: sense strand, 5-aattcGAGGAGACCGACAAGGAGCAGca-
agagaCTGCTCCTTGTCGGTCTCCTCtttttc; antisense strand, 5-tcgag-
aaaaaGAGGAGACCGACAAGGAGCAGtctcttgCTGCTCCTTGTCG-
GTCTCCTCg;ABINi-560: sense strand, 5-aattcCCACACCATGGCTT-
CGAGGACcaagagaGTCCTCGAAGCCATGGTGTGGtttttc; antisense
strand, 5-tcgagaaaaaCCACACCATGGCTTCGAGGACtctcttgGTCCT-
CGAAGCCATGGTGTGGg. The resulting double-stranded oligonucleo-
tides were cloned into the pcRNAi vector that we derived from the
pcDNA3.1vector (Invitrogen)by replacing theviral promoter cassettewith
the H1 gene promoter that is specifically recognized by RNA polymerase
III. The plasmids used to knockdown A20 expression (pU6-A20i and the
pU6)were a kind gift ofDr. S. Yamaoka andhavebeenpreviously described
(43).
RESULTS
ABIN-1 Binds to NEMO/IKK—The regulatory subunit of the IKK
complex, NEMO/IKK, has an essential role in NF-B activation. To
gain insights into how NEMO/IKK modulates the activation of
NF-B, we screened a human liver cDNA library for NEMO/IKK
interacting proteins, via the yeast two-hybrid system. 25 clones were
identified that expressed NEMO/IKK-interacting proteins, includ-
ing IKK and CARMA (23). Three clones encoded for overlapping
fragments of ABIN-1, a protein previously identified as an A20-bind-
ing protein that mimics the NF-B inhibiting effects of A20 (34).
To define the region of NEMO/IKK that interacts with ABIN-1, we
tested various deletion mutants of NEMO/IKK for binding to the
ABIN-1 fragment (amino acids 380–636) in yeast. Data shown in Fig.
1A indicate that the region between amino acids 50 and 100 of NEMO/
IKK is required for interaction with ABIN-1. The binding was con-
firmed in mammalian cells (Fig. 1B). HA-ABIN-1 was transiently co-
expressed in HEK293 cells together with FLAG-NEMO/IKK or a
NEMO/IKK mutant lacking the first 91 amino acids (FLAG-
FIGURE 2. Mapping of the NEMO/IKK and the
A20 binding domains on ABIN-1. A and B, GST
pull-down assays: GST-NEMO/IKKwas incubated
with in vitro translated full-length (FL) or deletion
mutants of ABIN. Aliquots of in vitro translated
constructs and GST-NEMO/IKK stained by Coo-
massie Blue are shown. C, co-immunoprecipita-
tion of FLAG-A20withHA-ABINor ABIN407–431.
HEK293 cells were transfected with FLAG-A20 and
either HA-ABIN or ABIN407–431. Cell extracts
were immunoprecipitated with anti-FLAG anti-
bodies (A20) followed by Western blot (WB)
anti-HA (ABIN). The presence ofHA andFLAG
proteins in total extracts is shown.
FIGURE 3. ABIN-1 and A20 are inhibitors of NF-B. A and B, ABIN-1 and A20 inhibit
NF-Bat level of the IKK complex. Relative reporter activitywas evaluated inHEK293 cells
co-transfected with the Ig-B-luciferase plasmid and the indicated expression vectors.
24 h after transfection cells were stimulated with TNF- for 3 h or left untreated, as
indicated. Values shown in arbitrary units represent the mean  S.D. of three experi-
ments done in triplicate, normalized for -galactosidase expression of a co-transfected
pRSV--galactosidase plasmid.
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NEMON91). Immunoprecipitates of FLAG-NEMO/IKK contained
HA-ABIN-1 only if both proteins were co-expressed (Fig. 1B, compare
lanes 3 and 4). In agreement with the data obtained in yeast, ABIN-1 did
not co-immunoprecipitate withNEMON91 (lane 6, Fig. 1B).Wewere
unable to detect the association between endogenousNEMO/IKK and
ABIN-1, probably because of the transient nature of the association
and/or the high stringent conditions we used to perform co-immuno-
precipitation experiments. However, gel filtration experiments showed
that endogenous ABIN-1 was eluted from the column in the same frac-
tions containing endogenous NEMO/IKK and other components of
IKK complex (Fig. 1C).
Mapping of the NEMO/IKK and the A20 Binding Domains on
ABIN-1—To define the domain of ABIN-1 required for its interaction
with NEMO/IKK, we performed pull-down assays by using recombi-
nant GST-NEMO/IKK and in vitro translated [35S]ABIN-1 (Fig. 2A).
ABIN-1 binds to GST-NEMO/IKK, indicating a direct interaction
between the two proteins. Furthermore, amino acids 500–588 of
ABIN-1 represent the minimal region that binds to NEMO/IKK (Fig.
2A, upper panel). To confirm that the region between amino acids 500
and 588 of ABIN-1 was responsible for interaction with NEMO/IKK,
we generated an internal deletion mutant of ABIN-1 (500–588) and
evaluated its ability to interact with NEMO/IKK. As expected, the
internal deletion of 89 amino acids from ABIN-1 abolished the interac-
tion with NEMO/IKK (Fig. 2B). Because ABIN-1 was identified as an
A20-interacting protein (35), we confirmed that the region between
amino acids 407 and 431 of ABIN-1 is responsible for interaction with
A20 (Fig. 2C).
Both ABIN-1 and A20 Inhibit NF-B at the Level of the IKK Complex
byAssociating withNEMO/IKK—BothABIN-1 andA20 are inhibitors of
NF-B. It has been proposed that they interfere with a RIP and TRAF2-
mediated transactivation signal (34). The identification of the interaction
between ABIN-1 and NEMO/IKK prompted us to investigate if ABIN-1
was involved in controllingNF-B activation not only upstreambut also at
the level of the IKK complex. To this aim, we performed reporter assays by
transfectingHEK293cellswith the Ig-B-luciferaseplasmid in thepresence
of ABIN-1 and various activators of NF-B. ABIN-1 efficiently inhibited
TNF- and TRAF2-dependent activation of NF-B (Fig. 3A). ABIN-1 also
blockedNF-B activation induced by proteins acting at the level of the IKK
complex, suchasCIKSandTAX(18–21). In contrast,ABIN-1wasnot able
to inhibit the IKK-mediated activation of NF-B (Fig. 3A). Similarly, A20
inhibits NF-B activation mediated by TNF- or ectopic expression of
TRAF2, CIKS, andTAXbut not IKK (Fig. 3B). These results indicate that
both ABIN-1 andA20 interfere with activation of NF-B at the level of the
IKKcomplex, suggesting that theassociationofABIN-1withNEMO/IKK
could play an important role in the inhibition of NF-B.
Because ABIN-1 interacts with both NEMO/IKK and A20, we
tested whether theNEMO/IKK- andA20-binding domains of ABIN-1
were required for inhibition ofNF-B.ABIN-1 deletionmutants lacking
FIGURE 4. ABIN-1 interacts with NEMO/IKK and A20 to inhibit NF-B activity. A–C, the deletion mutant of ABIN-1 lacking both NEMO/IKK- and A20-binding domains
(ABIN407–431/500–588) does not blockNF-B activation (C ), in contrast to ABIN500–588 (A) andABIN407–431 (B). HEK293 cells were co-transfectedwith the Ig-B-luciferase
reporter plasmid and the indicated combinations of expression plasmids. 24 h after transfection cells were stimulated with TNF- for 3 h or left untreated, as indicated. Analysis was
done as in Fig. 3. Lower panels in A–C show relative expression levels of each of the transfected proteins. D, ABIN-1 forms a complex with NEMO/IKK and A20. HEK293 cells were
transfectedwith constructs encoding NEMO/IKK, A20, and a deletionmutant of ABIN lacking the NEMO/IKK-binding domain (ABIN500–588). Cell extracts were immunoprecipi-
tatedwith anti-FLAG antibodies (NEMO/IKK) andWestern blotted (WB) anti-HA to reveal the co-precipitation of A20 andABIN500–588. The presence ofHAandFLAGproteins
in total extracts is shown. E, ABIN-1promotes associationofA20withNEMO/IKK. HEK293 cellswere transiently transfectedwith constructs encoding FLAG-NEMO/IKK, HA-A20, and
an increasing amount of His-ABIN. Cell extractswere immunoprecipitatedwith anti-FLAG antibodies (NEMO/IKK) andWestern blotted anti-HA to reveal the co-precipitation of A20.
The presence of ABIN, NEMO/IKK, and A20 in the whole cell lysate is shown.
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either the NEMO/IKK binding domain (ABIN500–588) or the A20
binding domain (ABIN407–431) were still able to inhibit the activity
of a NF-B-driven luciferase reporter following different stimuli (Fig. 4,
A and B). In contrast, a mutant of ABIN-1 in which both the NEMO/
IKK- and the A20-binding domains were deleted (ABIN407–431/
500–588) lost the ability to block activation of NF-B (Fig. 4C). These
data were consistent with the hypothesis that ABIN-1 forms a complex
with bothNEMO/IKK andA20. To address this hypothesis, we immu-
noprecipitated FLAG-NEMO/IKK and monitored the co-precipita-
tion of the ABIN-1 mutant lacking the NEMO/IKK-binding domain
(HA-ABIN500–588) either in the presence or absence of A20 (Fig.
4D). ABIN500–588 co-immunoprecipitated with NEMO/IKK only
in the presence of A20 (Fig. 4D). To further support the idea that
ABIN-1 promotes association ofA20withNEMO/IKK, we transfected
A20 andNEMO/IKK in the presence of an increasing amount of over-
expressedABIN-1. As expected, the amount ofA20 co-immunoprecipi-
tating with NEMO/IKK increased in the presence of ABIN-1 (Fig. 4E).
Taken together, these data indicated that ABIN-1 interferes with acti-
vation of NF-B at the level of the IKK complex, and support the idea
that ABIN-1 promotes association of A20 with NEMO/IKK.
A20 Inhibits NF-B by De-ubiquitinating NEMO/IKK—To explore
themechanism by which the interactions of both A20 and ABIN-1 with
NEMO/IKK down-regulate NF-B signaling, we assessed the effect of
either A20 or ABIN-1 on NEMO/IKK ubiquitination. Transfection of
FLAG-NEMO/IKK in the presence of HA-ubiquitin results in the
polyubiquitination of NEMO/IKK (Fig. 5A, lane 3). Co-transfection of
A20 and NEMO/IKK resulted in a dose-dependent disappearance of
the ubiquitinated forms of NEMO/IKK (Fig. 5A, lanes 4 and 5). In
contrast, co-transfection of ABIN-1 did not affect NEMO/IKK ubiq-
uitination (Fig. 5A, lanes 6 and 7). We did not observe reduction in the
overall level of ubiquitinated cellular proteins in the presence of A20,
indicating that A20 does not have a global de-ubiquitinating activity in
FIGURE 5. A20 inhibits NF-B by de-ubiquitinat-
ingNEMO/IKK. A, A20 but not ABIN-1 de-ubiquiti-
nates NEMO/IKK. HEK293 cells were transfected
with FLAG-NEMO/IKK and HA-ubiquitin, plus
increasing amounts of either HA-A20 or HA-ABIN.
Cell extracts were immunoprecipitated with anti-
FLAG antibodies (NEMO/IKK) followed by West-
ern blot analysis with anti-HA antibodies to reveal
the polyubiquitinated forms of NEMO/IKK. West-
ern blot analyses with anti-FLAG, -HA, -A20, -ABIN,
and -tubulin antibodies were performed on total
extracts. B, A20 blocks the ubiquitination of
NEMO/IKK and the degradation of IB induced
by TNF-. HEK293 cells were transfected with
FLAG-NEMO/IKK, HA-ubiquitin, andHA-A20. 24 h
after transfection cellswere stimulatedwith TNF-
for 5 min or left untreated, as indicated. Cell
extractswere immunoprecipitatedwith anti-FLAG
antibodies (NEMO/IKK) andWesternblottedwith
anti-HA antibodies. Western blots of anti-NEMO/
IKK, -IB, -A20, and -tubulin are shown. C, a cat-
alytically inactive formofA20 (D100A/C103S) does
not de-ubiquitinate NEMO/IKK. Conditions were
similar to those in A, except for the plasmids
encoding HA-A20 C103S, or D100A/C103S. D, A20
D100A/C103S does not inhibit NF-B activation
dependent on TRAF2 in contrast to wild type A20.
Reporter assay was performed by co-transfection
of the Ig-B-luciferase plasmid with combinations
of TRAF2, plus A20-WT, or -D100A/C103S. Values
shown in arbitrary units represent themean S.D.
of three experiments done in triplicate, normal-
ized for -galactosidase expression of a co-trans-
fected pRSV--galactosidase plasmid.
ABIN-1 Binds to NEMO/IKK
18486 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 27•JULY 7, 2006
 by on June 7, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
cultured cells (Fig. 5A). Importantly, A20 also blocks IB degradation
and NEMO/IKK ubiquitination induced by TNF- (Fig. 5B). To dem-
onstrate that the de-ubiquitinating activity of A20 was required for the
observed reduction in NEMO/IKK ubiquitination, we generated two
mutants in the OTU domain of A20, which is the domain responsible
for the de-ubiquitinating activity of A20 (36). We replaced the cysteine
residue of the DXXCmotif with serine (C103S), and both the aspartic
acid and the cysteine residues (D100A/C103S) with alanine and ser-
ine, respectively. The mutation C103S affected the ability of A20 to
de-ubiquitinate NEMO/IKK compared with wild type A20,
whereas the double mutant D100A/C103S resulted in the complete
loss of the de-ubiquitinating activity of A20 on NEMO/IKK (Fig.
5C). As expected, the D100A/C103S mutant was not able to block
the NF-B activity induced by different stimuli, such as TRAF2 (Fig.
5D and data not shown).
These findings strongly suggest that NEMO/IKK is a target of the
de-ubiquitinating activity of A20 and confirmed that the ubiquitination
ofNEMO/IKK is a crucial step in themechanisms ofNF-B activation.
ABIN-1 Mediates the De-ubiquitinating Activity of A20 on
NEMO/IKK—Next, we explored whether ABIN-1 was involved in the
A20-dependent de-ubiquitination ofNEMO/IKK. To this purpose, we
transfected HEK293 cells with a suboptimal amount of A20 and an
increasing amount of ABIN-1 and checked for NEMO/IKK ubiquiti-
nation. We found that ABIN-1 increases the ability of A20 to de-ubiq-
uitinate NEMO/IKK (Fig. 6A). To demonstrate a role for ABIN-1 in
the A20-mediated de-ubiquitination of NEMO/IKK, we generated
siRNA constructs targeting ABIN-1 (ABINi-370 and i-560). Fig. 6B
shows that the construct i-370 knocked-down ABIN-1 expression,
whereas the i-560 construct did not. Then, we evaluated whether inter-
ference of ABIN-1 impairs the de-ubiquitinating activity of A20 on
NEMO/IKK. We co-transfected HEK293 cells with FLAG-NEMO/
IKK and HA-ubiquitin and assessed the de-ubiquitinating activity of
A20 alone or in the presence of either i-370 or i-560 constructs. The
A20-dependent de-ubiquitination of NEMO/IKK decreased only in
the presence of the i-370 construct (Fig. 6C). The i-370 construct led to
a 2-fold increase of both basal and induced (TRAF2 and CIKS) NF-B
activity compared with the empty vector or the i-560 construct, which
we used as controls (Fig. 6D). Accordingly with the data shown in Fig.
3A, interferenceofABIN-1didnot influence theactivationof theNF-B-
dependent transfected IKK. Also in this case, NF-B activity corre-
lated with the levels of NEMO/IKK ubiquitination. In fact, transfected
i-370 increased the ubiquitination of NEMO/IKKwith respect to both
empty vector and i-560 (data not shown). From these experiments, we
concluded that reduced levels of the ABIN-1 protein affect the ability of
FIGURE 6. ABIN-1 participates to the A20-dependent de-ubiquitination of NEMO/IKK. A, ABIN-1 increases the effects of A20 on NEMO/IKK ubiquitination. HEK293 cells were
transfected with FLAG-NEMO/IKK, HA-ubiquitin, suboptimal amounts of HA-A20, and increasing amounts of HA-ABIN. Cell extracts were immunoprecipitated with anti-FLAG
antibodies (NEMO/IKK) and analyzed by Western blot for anti-HA. Western blots of anti-FLAG, -A20, -ABIN, and -tubulin are shown. B, RNA interference of ABIN-1. HEK293
cells were transiently transfected with siRNAs targeting ABIN (ABINi-370 or -560). ABIN expression was analyzed by immunoblotting with antibodies against ABIN. Equiva-
lency of protein loading is shown in the tubulin and NEMO/IKK blots. C, ABIN-1 siRNAs impairs the A20-dependent de-ubiquitination of NEMO/IKK. HEK293 cells were co-
transfectedwith FLAG-NEMO/IKK, HA-ubiquitin, and -A20, plus eitherABINi-370or -560. Cell extractswere immunoprecipitatedwith anti-FLAGantibodies andWesternblottedwith
anti-HA. Western blots of anti-FLAG, -A20, and -tubulin were performed on total extracts. D, ABIN-1 siRNAs increase NF-B activation by TRAF2 and CIKS. HEK293 cells were
co-transfected with TRAF2, CIKS, or IKK, plus Ig-B-luciferase reporter and either ABINi-370 or -570. 24 h after transfection cells were stimulated with TNF for 3 h or left untreated.
Analysis was done as in Fig. 5D. E, RNA interference of A20 impairs the ABIN-1-mediated inhibition of NF-B. Relative reporter activity was evaluated in HEK293 cells co-transfected
with the Ig-B-luciferase reporter, TRAF2, and either A20i or CTLi plasmids. 24 h after transfection cells were stimulated with TNF- for 3 h or left untreated, as indicated. Analysis of
luciferase activity was done as above.
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A20 to de-ubiquitinate NEMO/IKK and, consequently the A20-medi-
ated inhibition of NF-B. To further support the functional interplay
between ABIN-1 and A20, we knocked-down A20 (43) and evaluated
the ability of ABIN-1 to interfere with NF-B activation. As shown in
Fig. 6E, ABIN-1 requires A20 to efficiently block NF-B activation
induced by TNF and TRAF2.
DISCUSSION
In the present study, we have performed experiments in yeast, in vitro
and in transfected cells demonstrating that ABIN-1 physically associ-
ates with NEMO/IKK. The functional consequence of this interaction
is that overexpression of ABIN-1 blocks not only activation of NF-B
upstream of the IKK complex, but also NF-B activation mediated by
proteins directly contacting the IKK complex, such as CIKS and TAX.
Indeed, activation of NF-B mediated by overexpression of IKK,
which may be considered functionally downstream of NEMO/IKK, is
not affected by ABIN-1. ABIN-1 has been identified as an A20-binding
protein and its overexpression mimics the inhibitory effect of A20, sug-
gesting that ABIN-1, at least partially, mediates the inhibitory function
of A20. A20 is a TNF- responsive gene that inhibits NF-B-dependent
gene transcription in response to TNF- and other stimuli (37–39).
Given that A20 expression itself is regulated byNF-B, it is possible that
A20 and ABIN-1 participate in a negative feedback regulation of NF-B
activation (40, 41). However, the mechanism by which ABIN-1 partici-
pates in this process is not clear. We provide evidence that ABIN-1 and
A20 co-operate to promote de-ubiquitination of NEMO/IKK, which
results in functional inactivation of NF-B. In fact, recent studies have
indicated ubiquitination as a key event in the regulation of NF-B acti-
vation. For example, A20 modifies the ubiquitination profile of RIP in a
two-step model, by removing the Lys63-linked ubiquitin chain and by
the subsequent ligation of the Lys48-linked ubiquitin chain (30). Simi-
larly, A20 inhibits Toll-like receptor signaling by removing the Lys63-
linked ubiquitin chain from TRAF6 (27). In this context our data dem-
onstrate that NEMO/IKK is an additional target of the
de-ubiquitinating activity of A20. Currently, it is not clear if A20 directly
de-ubiquitinates NEMO/IKK, or it affects the activity of other pro-
tein(s) regulating NEMO/IKK ubiquitination. However, we have now
shown that in cells knocked-down for ABIN-1, we observed a decrease
in the ability of A20 to de-ubiquitinate NEMO/IKK, and that in cells
knocked-down for A20, the inhibitory function of ABIN-1 is impaired.
Altogether our data strongly suggest that ABIN-1 functionally connects
A20 and NEMO/IKK.
In summary, we have identified a previously not reported association
between ABIN-1 and NEMO/IKK and we provide evidence that
ABIN-1 co-operateswithA20 in inhibitingNF-B at the level of the IKK
complex. In addition, we propose that this association could target A20
on NEMO/IKK and interfere with NEMO/IKK ubiquitination, to
negatively regulate NF-B activation.
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ABSTRACT
A young man, presenting with early onset of personality
and behavioural changes followed by slowly progressive
cognitive impairment associated with marked bi-parietal
cerebral atrophy, was found to carry a novel seven extra-
repeat insertional mutation in the prion protein gene
(PRNP). In vitro, the mutated recombinant prion protein
(PrP) showed biochemical properties that were consistent
with pathological PrP variants. Our results further under-
line the heterogeneity of neurological pictures associated
with insertional mutations of PRNP, indicating the
diagnostic difficulties of sporadic cases with early-onset
atypical dementia.
Prion diseases are a heterogeneous group of
neurodegenerative disorders, including sporadic,
genetic and acquired forms. The causative agent
consists of conformationally altered forms of a
host-encoded glycoprotein (PrPC), termed PrPSc.1
The genetic forms of prion diseases are associated
with point or insertional mutations in the PrP gene
(PRNP). PrPC carries one nonapeptide (R1) and four
octapeptides (R2, R2, R3, R4) between codons 51
and 91, which have the same amino-acid sequence
but can be distinguished by variations in their
DNA sequence. Insertional mutations consist of
one, two, four, five, six, seven, eight or nine extra
octapeptide repeats in PRNP. Although patients
with one, two or four extra repeats have typical
Creutzfeldt–Jakob disease (CJD), the clinico-patho-
logical features of patients with five, six, seven,
eight and nine extra repeats are reminiscent of
Gerstmann–Stra¨ussler–Scheinker disease or atypi-
cal dementia.2 3
Here, we report a patient with an early onset,
slowly progressive disease, manifesting personality
and behavioural changes followed by atypical
dementia, carrying a novel seven-octarepeat inser-
tional mutation in PRNP. The results obtained in
vitro on the mutant recombinant protein are
consistent with previously reported data about
the effects of the insertional mutations over the
biochemical properties of the protein.4
PATIENT AND METHODS
Patient history
A 27-year-old man presented with slowly progres-
sive behavioural changes and cognitive impair-
ment, without familial history of dementia or
psychosis. The pre-clinical history revealed that, as
a teenager, he was an active, competitive and well-
adapted person, even a successful student. At 19
years of age, the disease became manifest with loss
of social interests, apathy, emotional indifference
and progressive isolation at home. A few years
later, learning difficulties became prominent,
mostly dependent on attention deficit.
Hallucinations and/or delirium were not reported.
During this early phase, the diagnosis of psychosis
or depression was formulated and the patient was
treated with neuroleptics and anti-depressive
drugs, without any efficacy. In the past 2 years
before our observation, he developed apraxia.
Our neurological evaluation revealed visuo-spa-
tial and constructional defects, ideomotor apraxia,
mild left–right confusion, dyscalculia and bilateral
cortical dysestesia, although no ataxia, pyramidal
or extrapyramidal signs were present.
Extensive viral, metabolic, endocrine and immu-
nological investigations were unrevealing.
Cerebrospinal fluid analysis was normal, including
determination of 14.3.3 and tau proteins.
Electroencephalographic (EEG) studies showed
frequent diffuse and bilateral paroxysmal slow
waves, prevailing posteriorly. Magnetic resonance
imaging (MRI) and positron emission tomography
(PET) disclosed diffuse cortical atrophy and reduc-
tion of 18-Fluoro-2-Deoxy-D-glucose (FDG) meta-
bolism, mostly in the parietal lobes and
particularly in the posterior parietal gyrus (fig 1A,
B).
Genetic analysis
Sequence analysis of full-length coding region of
PRNP, of microtubule-associated protein Tau
(MAPT), and of exons 16 and 17 of amyloid beta
precursor protein (AbPP) was performed.
More than 1 year later, the patient received
further genetic counselling at another institution,
and his case was briefly described.5
Peripheral blood leukocyte (PBL) analysis
Peripheral blood leukocytes (PBLs) from a control
and the patient were purified by centrifugation and
lysed in Laemmli buffer. Aliquots (40 ml) of super-
natant were analysed by Western blot using
monoclonal antibodies 3B5 (gift of Prof. G.
Hunsmann, Go¨ttingen, Germany—epitope at resi-
dues 79–92 of human PrP)6 and 3F4 (Dako,
Carpinteria, CA; epitope at residues 109–112 of
human PrP).
Cloning of wild-type PrP and mutated recombinant
PrP with seven extra repeats
Total RNA was isolated from the patient’s PBLs
using the Chomczynski and Sacchi method.7
Primers to amplify wild-type PrP (WT-PrP) and
mutated recombinant PrP with seven extra repeats
Short report
J Neurol Neurosurg Psychiatry 2008;79:1395–1398. doi:10.1136/jnnp.2007.142976 1395
 on 21 November 2008 jnnp.bmj.comDownloaded from 
(M7-PrP) were designed on the basis of the PrP cDNA sequence
(GenBank accession number BC022532): forward, 59-
CCGGAATTCGCCGCCATGGCGAACCTTGGCTGC-39; reverse,
59-TCTTCTAGATCCCACTATCAGGAAGATGAGG-39.The
amplified bands were cloned in the p-CMV vector for
expression in mammalian cells. Cloned cDNA fragments were
analysed by automatic DNA sequencing.
The detergent solubility and the proteinase K (PK) resistance
assays were carried out on HEK-293 transfected cells, as
previously described,3 with slight modifications (ie, PK diges-
tion: 5, 10 and 20 mg/ml, 37uC, 30 minutes).
RESULTS
Genetic analysis of the proband disclosed the presence of an
insertional mutation consisting of seven extra repeats in PRNP
(fig 1C). The polymorphism at codon 129 was methionine/
methionine. According to Goldfarb’s nomenclature,8 the repeats
of the mutant allele were arranged as follows: R1-R2-R2-R3-R2-
R2-R3g-R2-R2-R2-R3-R4. Although the differences in nucleo-
tides did not modify the amino-acid sequence of the octapep-
tides, DNA sequencing established that our patient carried a
new PRNP insertion of 168 bp. This mutation was not present
in his parents (study of the haplotypes excluded a paternity
error). No mutations were found in AbPP and MAPT genes.
Western blot on the patient’s PBLs revealed the expression of
both mutant M7-PrP and WT-PrP (fig 1D). Both proteins were
PK-sensitive and detergent-soluble.
When expressed in HEK-293 cells, M7-PrP revealed abnormal
properties, showing PK resistance up to an enzyme concentra-
tion of 10 mg/ml (fig 2A) and detergent insolubility (fig 2B). PK
digestion produced no shift in molecular weight, but increased
the amount of a low molecular weight ,11 kDa fragment,
which was already present in PK untreated samples. Although
WT-PrP was exclusively detected in a detergent-soluble fraction,
the ,11 kDa fragment and about 50% of the full-length M7-PrP
were detergent insoluble.
WT- and M7-PrP disclosed a different glycosylation pattern,
with a significant increase of the non-glycosylated and mono-
glycosylated immature forms in M7-PrP (fig 2C). This result is
suggestive of an altered folding of M7-PrP. To further support
the finding that M7-PrP does not fold properly, we took
advantage of the knowledge that unfolded and misfolded
proteins are retro-translocated from the lumen of the ER to
the cytosol and degraded through a proteosome-dependent
mechanism, and checked the glycosylation pattern of WT- and
M7-PrP after blocking the proteosome activity. Figure 2D shows
an increase of the non-glycosylated form only in M7-PrP,
following inhibition of proteosome by Calpain Inhibitor-I.
DISCUSSION
Here, we report a novel large insertional mutation in PRNP
associated with early-onset and slowly progressive encephalo-
pathy, leading to focal brain atrophy. To date, it represents the
first reported de novo extra-repeat insertional mutation in PRNP.
The likeliest genetic mechanism proposed for this spontaneous
mutation is (multi-stage) replication strand slippage,9 10 which
probably occurred spontaneously in the parents’ spermatogen-
esis/oogenesis—that is, during the DNA replication process, the
daughter strand experiences slippage facilitated by complemen-
tarity to an earlier template repeat. Repeats, by their nature, are
still complementary when misaligned by an integral multiple of
24 bp. Exonuclease editing 39 to 59 is available to remove
mismatches. Partial editing produces chimeric repeats. When
replication resumes with slipped complementarity in place, the
result is extra repeats. Longer complex repeats require multiple
rounds of stalling, slipping, editing and resuming replication,
until finally replication run-out occurs. The imbalance of
reciprocal recombinants, complexity of some variants and
Figure 1 Brain atrophy and reduction of
FDG/metabolism marked in parietal
convexity bilaterally at MRI (A) and PET/
FDG (B). Ethidium bromide-stained
fragments of the PCR-amplified repeat
region (F4-R4 primers) of PRNP (C). The
parents (lanes 2,3) show a single band of
193 bp. The patient (lane 1) shows an
additional fragment of 371 bp derived
from the allele containing the insertional
mutation. In (D), PrP expression into
peripheral blood leucocytes before and
after proteinase K (PK) digestion (2, 5 and
10 mg/ml) and deglycosylation (PNGase)
is seen. Compared with the normal
control (lane 1), the patient with the
insertional mutation (lane 2) shows an
additional band of ,39 kd before
deglycosylation and ,32 kd after
deglycosylation (lane 3), which
corresponds to full-length mutated
recombinant PrP with seven extra repeats
(M7-PrP). After PK incubation, control and
M7-PrP are completely digested (lanes 4–
7). Western blot analysis (3F4 antibody,
1:50,000).
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generational stability are implausibly implemented via unequal
recombination.
Four kindreds with seven extra-repeat mutations have been
described so far,8 11 12 all presenting a dominant pattern of
inheritance and phenotypically distinct from the present case.
In our case, as in all cases reported with a similar insertion, the
mutation was in heterozygosis and in frame with methionine at
codon 129 of PRNP. As previously reported in other octapeptide
repeat insertions,13 here it is confirmed that the 129-methio-
nine/methionine polymorphism is associated with early onset
of disease, but not with the phenotype of the disease and the
rate of clinical progression.
We lack neuropathological study of our patient; however, all
the data available in the literature about other kindreds with
seven extra repeats of PRNP insertional mutation indicate the
pathogenicity of this genetic defect, with the neuropathological
hallmark lesions of prion diseases and transmission of the
spongiform encephalopathy into primates.8
Our in vitro experiments support the idea that the PRNP
mutation of our patient had a causal role. The mutated
recombinant prion protein (M7-PrP) that was ectopically
expressed in HEK-293 cells showed partial PK resistance and
detergent insolubility, which are typical characteristics of PrPSc.
It is noteworthy that PK resistance was present even at higher
PK concentration and longer digestion time than previously
reported.4 14 15 Further support to the abnormal properties of
M7-PrP came from the finding of a low molecular weight
fragment (,11 kDa) reminiscent of GSS amyloid protein,16 that
increased after PK digestion and was detergent insoluble.
The tendency to misfolding of the recombinant M7-PrP is
evoked by its altered glycosylation pattern, which suggests a
build-up in the ER and an inefficient transport to the cell
surface.17 This can be explained taking into account that
membrane and secreted proteins are submitted to a strict
control that is aimed at preventing the transport of misfolded
proteins from the ER to the cellular surface by means of the
retro-translocation in the cytosol and degradation through the
proteasome. Further support of this hypothesis came from the
observation that inhibition of proteasomes resulted in an
increase in the non-glycosylated immature glycoform of
mutated recombinant PrP.
From a clinical point of view, our case showed some
similarities with other patients, reported in the literature,
carrying seven extra-repeats of insertional mutation, such as
cognitive decline, long duration of disease and apraxia.8 11 18 19
However, it is unique because of early onset with personality
changes and autistic-like behaviour, slow progressive course, a
pattern of focal dementia correlated to marked parietal atrophy
and absence of cerebellar ataxia.
This study highlights the importance of searching the
aetiology of early-onset sporadic dementia presenting with
psychiatric features by screening for mutations of the PRNP,
also considering some similarities with variant CJD.20
Competing interests: None declared.
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NF-B is constitutively activated in primary human thyroid tumors,
particularly in those of anaplastic type. The inhibition of NF-B
activity in the human anaplastic thyroid carcinoma cell line, FRO,
leads to an increased susceptibility to chemotherapeutic drug-
induced apoptosis and to the blockage of their ability to form
tumors in nude mice. To identify NF-B target genes involved in
thyroid cancer, we analyzed the secretome of conditioned media
from parental and NF-B-null FRO cells. Proteomic analysis re-
vealed that the neutrophil gelatinase-associated lipocalin (NGAL),
a protein involved in inflammatory and immune responses, is
secreted by FRO cells whereas its expression is strongly reduced in
the NF-B-null FRO cells. NGAL is highly expressed in human
thyroid carcinomas, and knocking down its expression blocks the
ability of FRO cells to grow in soft agar and form tumors in nude
mice. These effects are reverted by the addition of either recom-
binant NGAL or FRO conditioned medium. In addition, we show
that the prosurvival activity of NGAL is mediated by its ability to
bind and transport iron inside the cells. Our data suggest that
NF-B contributes to thyroid tumor cell survival by controlling iron
uptake via NGAL.
Cancer is a multistep process during which cells undergoalterations of their normal functions that progressively
lead to the genesis of a tumor. Among the most significant
changes, cancer cells begin to secrete, into the tumor micro-
environment, a number of factors that stimulate their own
growth/survival and mediate angiogenesis and metastasis.
During the last years, the role of NF-B in the pathogenesis of
human cancer has strongly emerged. In particular, because it
is now generally accepted that chronic inf lammation contrib-
utes to the genesis of many solid tumors, such as gastric, colon,
or hepatic carcinomas, it has been recently shown that acti-
vation of NF-B by the classical IKK-dependent pathway is
a crucial mediator of inf lammation-induced tumor growth and
progression in animal models of inf lammation-associated can-
cer (1, 2). This is not particularly surprising given that NF-B
controls expression of a number of proinf lammatory factors
(cytokines, chemokines ,and growth factors), secreted by
cancer cells in the tumor microenvironment, that substantially
contribute to tumor development (3, 4). Understanding the
molecular mechanism by which these factors play their role in
cancer could help in the comprehension of the role of NF-B
in inf lammation-related cancer and could open innovative
perspectives in the treatment of tumors.
We have shown that NF-B is strongly activated in human
anaplastic thyroid carcinomas (ATCs) (5). To study the role of
NF-B in thyroid cancer, we inhibited its function by stably
transfecting FRO cells (derived from a human ATC) with a
super-repressor form of IB (IBM). As a result, FRO
IBM cells lost their oncogenic potential mainly from an
increased susceptibility to drug-induced apoptosis (5).
The neutrophil gelatinase-associated lipocalin (NGAL),
also known as lipocalin-2, is a member of a large family of
lipocalins, a group of small extracellular proteins with great
functional diversity (6). It is released from neutrophil granules
as a 25-kDa monomer, a 46-kDa disulfide-linked homodimer,
and a 135-kDa disulfide-linked heterodimer with a matrix
metalloproteinase-9 (MMP-9) (7). NGAL is thought to be an
acute phase protein (8) whose expression is up-regulated in
human epithelial cells under different inf lammatory condi-
tions, such as inf lammatory bowel disease (9). Elevated NGAL
expression has also been shown in different human tumors
including breast (10), lung (11), colon (9), ovary (12), and
pancreas (13) carcinomas. However, the precise role of NGAL
has not been well defined. Several studies have suggested that
NGAL is a potent bacteriostatic agent that has siderophore-
mediated sequestering of iron (14, 15), and that it is capable
of protecting MMP-9 from autodegradation, thereby favoring
the metastatic potential of cancer cells (16). As a secreted
binding protein, it has been reported that the murine ortholog,
24p3, plays a crucial role in IL-3 deprivation-induced apoptosis
by regulating intracellular iron delivery, very likely after
interaction with a 24p3 receptor (17). Indeed, the human
NGAL protects A459 and MCF7 cells from apoptosis induced
by PDK1 inhibitors (18). Last, NGAL induces cell prolifera-
tion by promoting the iron-dependent metabolism of nucleo-
tides for DNA synthesis (19).
The cellular system FRO/FRO IBM represents an excel-
lent model for the identification of NF-B-regulated factors
that, when secreted in the extracellular milieu, could play a
role in thyroid cancer. Thus, we used a different proteomic
approach to analyze the pattern of expression of secreted
proteins from conditioned medium of parental FRO cells and
FRO IBM clones. One of the proteins that showed a marked
decrease of expression in FRO IBM cells was NGAL. We
show that knocking down NGAL expression blocks the ability
of FRO cells to form colonies in soft agar and tumors in nude
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mice and, therefore, increases their susceptibility to apoptosis.
In addition, we show that the prosurvival activity of NGAL is
mediated by its ability to bind and transport iron inside the
cells.
Results
Differential Proteomic Analysis of Conditioned Media from FRO and
FRO IBM Cell Lines. To identify factors secreted by thyroid
cancer cells under transcriptional control of NF-B, we analyzed
the secretome of partially purified conditioned media from FRO
and FRO IBM cell lines. Among the proteins whose expres-
sion decreased in the extracellular medium of FRO IBM cells,
as compared with FRO, at least three groups were examined
because of their strong reduction (Fig. 1 A, circled spots). The
MALDI-TOF peptide mass fingerprint analysis identified all
spots as NGAL, whose modifications after translation account
for the multiple species that show variable molecular weight and
pI values in the 2-DE gel.
Northern and Western blot assays confirmed the decreased
expression of NGAL in FRO IBM cells, as compared with
parental FRO cells [supporting information (SI) Fig. S1 A–C].
To confirm that NF-B was controlling NGAL expression, we
knocked down p65 expression in FRO cells by using siRNA and
detected a decreased NGAL expression by Western blot analy-
sis(Fig. S1D). In addition, WT and p65/ mouse embryonic
fibroblasts (MEF) were treated with IL1 or IL17, and the
NGAL expression was detected by Northern and Western blot
assays (Fig. S1 E and F). No induction of NGAL was detected
in absence of p65. Reexpression of p65 in p65/MEF restored
NGAL expression (Fig. S1G).
It was demonstrated that NF-B controls NGAL expression
via the inducible cofactor IB (20, 21). We then investigated, by
using chromatin immunoprecipitation, whether, in FRO cells,
IB was also bound to the NGAL promoter. As shown in Fig.
S2, IB was bound to the NGAL promoter together with the
p50 and the p52 subunits of NF-B.
Immunohistochemical Analysis of NGAL Expression in Normal and
Pathological Human Thyroid Specimens. To verify the expression of
NGAL in human primary thyroid cancer, we analyzed normal
thyroid specimen and specimen from different thyroid carcino-
mas by immunostaining. As shown in Table 1 and Fig. 1 B–G,
although NGAL expression was not detected in normal thyroid,
NGAL immunostaining was positive for papillary, follicular and
ATC. The levels of NGAL expression increased with the ma-
lignant phenotype of tumors, reaching the highest intensity in the
anaplastic carcinomas (Table 1 and Fig. 1 B–G), in parallel with
NF-B basal activity in the same types of thyroid tumors (5).
Real time PCR analysis confirmed the increased expression on
the NGAL mRNA in primary human thyroid cancer (Fig. 1H).
Inhibition of NGAL Expression Leads to the Blockage of Tumorigenicity
in FRO Cells. To study the role of NGAL in thyroid cancer, we
blocked its expression in FRO cells by stable transfection of a
siRNA targeting NGAL. Fig. 2A shows the levels of NGAL
protein in two of the clones analyzed (indicated as siRNANGAL
2/2 and 2/6) in FRO cells, either transfected with the empty
vector (FRO Neo cells) or transfected with a control siRNA
FRO FRO IκBαM
8.5 9.5
pH
20
MW
(kDa)
A
E
B
8.5 9.5
pH
N
G
A
L
/G
A
PD
H
 m
R
N
A
(a
rb
itr
ar
y
un
its
)
H
0
20
40
60
80
100
NT PTC FTC ATC
*
*
*
F G
C
D
Fig. 1. Analysis of NGAL expression. Two-dimensional gel electrophoresis
showing expression of NGAL in the conditioned medium of FRO IBM cells,
as compared with parental counterpart FRO (A). Localization of NGAL in situ
was determined by immunohistochemistry in sections from normal thyroid
tissue (B) and three different ATCs (C–E). Lack of specific tissue staining was
seen when either secondary Abs (F) or blocked Abs (G) were used. Magnifi-
cation: 400. (H) qRT-PCR analysis of NGAL mRNA levels in primary human
cancers. NT, normal thyroid (n  2); PTC, papillary thyroid carcinoma (n  3);
FTC, follicular thyroid carcinoma (n  3); ATC, anaplastic thyroid carcinoma
(n  3). *, P  0.0005.
Table 1. Immunohistochemical analysis of NGAL expression in normal and pathological human thyroid tissues
Histological type of thyroid samples
Number of total
cases analyzed
Number of positive cases/
Number of total cases analyzed
NGAL staining score
0 1 2 3
Normal thyroid 3 0/3 3
Papillary carcinoma 14 9/14 5 4 3 2
Follicular carcinoma 8 5/8 3 2 3
Anaplastic carcinoma 7 6/7 1 2 4
Human specimens were stained with anti-NGAL polyclonal antibodies. The percentage of malignant cells stained was scored from 0 to 3: 0, no positive cells;
1, 10% of positive cells; 2, 11–60% of positive cells; 3, 61–100% of positive cells.
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(indicated as siRNA NGAL 220/22). Fig. 2B shows the levels of
secreted NGAL. These clones were tested for their ability to
grow in semisolid medium and to form tumors in nude mice. In
in vitro experiments, whereas FRO, FRO Neo, and 220/22 cells
gave rise to foci of transformation, 2/2 and 2/6 clones did not
form any colonies (Fig. 2C andD). In in vivo assays, the injection
of parental FRO or 220/22 cells into nude mice induced tumor
formation in 12 of 12 mice, whereas the injection of 2/2 or 2/6
cells induced tumor formation in 1 of 6 and 4 of 6 mice,
respectively (Table 2). The tumors developed from 2/2 and 2/6
cells were 4-fold and 2-fold smaller than those formed after
injection of parental cells, respectively (Table 2). Notably, 2 of
4 tumors from 2/6 cells showed NGAL staining after immuno-
histochemical analysis, indicating that the expression of the
siRNA plasmid was lost. We also blocked NF-B in FRO cells
by transient overexpression of IBM. In the absence of func-
tional NF-B, FRO cells did not form colonies in soft agar.
Reexpression of NGAL partially rescued the ability of FRO cells
to form colonies in soft agar (Fig. S3 A–C).
NGAL Is a Survival Factor in FRO Cells.We analyzed the response of
parental FRO cells and NGAL siRNA clones to serum with-
drawal-induced apoptosis. All clones grown in the presence of
serum showed 2–3% apoptosis, as assessed by propidium iodide
staining (Fig. 3A). Serum deprivation did not affect the survival
of FRO, FRO Neo, and 220/22 clones but induced a significant
cell death (10–15%) in 2/2 and 2/6 clones (Fig. 3A). This effect
was reverted by the addition of the conditionedmedium of either
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Fig. 2. Inhibition of NGAL expression by siRNA and in vitrooncogenic activity
of the siRNA clones. The expression of NGAL in FRO cells, stably transfected
with either siRNA plasmids (2/2, 2/6), control siRNA plasmid (220/22), or empty
vector (Neo), was determined by Western blot analysis on total cell lysates (A)
and on conditioned media (B). (C) Colony formation assay. Colonies50 cells
were scored after 2 weeks incubation at 37°C (D). Magnification:200. *, P
0.0001 (2/2 and 2/6 vs. FRO, FRO-Neo, and 220/22).
Table 2. In vivo tumor growth induced by FRO Neo cells and FRO siRNA NGAL clones
Cell type Tumor incidence
Tumor volume
average, cm3
Tumor weight
average, g
FRO 6/6 0.37  0.04 0.24  0.05
FRO siRNA NGAL 2/2 1/6 0.01*** 0.05***
FRO siRNA NGAL 2/6 4/6 0.16  0.06** 0.11  0.02**
FRO siRNA NGAL 220/22 6/6 0.33  0.02 0.21  0.03
2  107 cells were injected s. c. on a flank of each 6-week-old nude mouse. Tumor weight, diameter, and volume values were measured and determined as
described in the SI Text. Two of four tumors developed by mice injected with FRO siRNA 2/6 cells showed partial NGAL staining after immunohistochemical
analysis. ***, P  0.0001 (FRO 2/2 vs. FRO); **, P  0.001 (FRO 2/6 vs. FRO).
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withdrawal. 2.5  105 cells per well were seeded in 6-well culture plates and
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FRO cells, FRO Neo cells, or 220/22 cells, to 2/2 and 2/6 clones.
The same effect was also seen in the FRO cells transiently
transfected with IBM (Fig. S3D). To confirm the activation of
the apoptotic machinery, we analyzed by using Western blot
analysis, the caspase-9 activity in parental FRO cells and NGAL
siRNA clones grown in the same experimental conditions used
in the propidium iodide assay (Fig. 3B). Serum deprivation
induced cleavage of caspase-9 in 2/2 and 2/6 clones but not in
parental FRO cells (Fig. 3B). Also, in this case, incubation of
NGAL siRNA clones with the conditioned medium of FRO
cells, FRO Neo cells, or 220/22 cells restored their survival (Fig.
3 A and B). These data strongly suggest that NGAL is a survival
factor for thyroid carcinoma cells.
A dissection of the apoptosis pathways is illustrated in Fig. S4.
In the NGAL siRNA clones grown in absence of serum, the
initiating caspases-2 and -9 and the execution caspases-3 and 7
are activated, whereas the activity of other caspases (such as the
initiating-, receptor-associated caspase-8) are not. This effect is
reverted by the addition of either recombinant NGAL or iron
(Fig. S4A). A very similar pattern of caspases activation is
detected in FRO or 220/22 cells incubated with deferoxamine
(DFO). Iron deprivation also resulted in the decrease of mito-
chondrial membrane potential (Fig. S4B) and in the release of
cytochrome C (Fig. S4C). These data suggest that iron depriva-
tion induces apoptosis via collapse of the mitochondrial mem-
brane potential, release of cytochrome C from mitochondria,
and activation of execution caspases.
NGAL-Mediated Intakeof Extracellular IronAccounts for theAntiapop-
totic Activity of NGAL in FRO Cells.One of the properties of NGAL
is an ability to deliver iron from the extracellular milieu into the
cells. Because it has been described that iron could play an
important role in cancer and apoptosis (22), we tested whether
the increased susceptibility of siRNA NGAL clones to cell death
was because of the decreased NGAL-mediated delivery of iron.
We first analyzed the ability of iron-loaded transferrin and
NGAL to rescue siRNA NGAL clones from serum deprivation-
induced apoptosis. As reported in Fig. 4, both propidium iodide
staining (A) and Western blot anti-caspase-9 (B) showed that
addition of transferrin or recombinant NGAL to the serum-free
medium restored the survival of siRNA clones.
To further confirm that NGAL acts as a survival factor for
cancer cells by delivering iron, we used DFO (an iron chelator)
and ferric chloride (FeCl3, an iron source) to evaluate the
survival of the siRNA clones.When cells were grown in complete
medium in presence of DFO, both parental FRO cells and
derived siRNA clones underwent apoptosis (Fig. 4 C and D).
However, FeCl3 produced the opposite effect; it restored the
resistance of siRNANGAL clones to serum deprivation-induced
apoptosis (Fig. 4 E and F).
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Because these results indicated that the intracellular iron
content could be relevant for the survival of FRO cells, we
analyzed the intracellular iron concentration of parental FRO
cells and NGAL siRNA clones (Fig. 5). The colorimetric assay
showed that 2/2 and 2/6 clones lacked at least 20–30% of iron
content (P  0.05) compared with FRO, FRO Neo, and 220/22
cells, thus suggesting that the absence of NGAL determined a
decrease of iron uptake in the clones.
Discussion
We have identified NGAL as a mediator of the NF-B onco-
genic activity in thyroid cancer. NGAL is highly expressed in the
human thyroid carcinoma FRO cell line and other poorly
differentiated thyroid cancer cell lines (Fig. 1A and data not
shown), is highly expressed in primary human ATC (Fig. 1 B–E
and Table 1), and acts as a survival factor for thyroid cancer cells
(Figs. 3 and 4). The prosurvival activity of NGAL is mediated by
its ability to bind iron and to transport it inside the cells (Figs.
4 and 5). These findings show that NGAL is a critical effector of
NF-B-mediated oncogenic activity, defines a prosurvival func-
tion of NGAL, and highlights iron as a central controller of cell
survival.
Various types of cancers express high levels of NGAL, in-
cluding colon, pancreas, breast, bladder, and liver (9–13). NGAL
represents the human homolog of the rat neu-related lipocalin,
a gene that was shown to be overexpressed in HER-2/neu
oncogene-induced rat mammary tumors (23). Whether NGAL
is causal or contributory to cancer is unknown. It has been
reported that NGAL is a surviving factor for cancer cells.
Ectopic expression of NGAL in lung and breast cancer cell lines
reduced the apoptosis that was induced by a PDK1 inhibitor
whereas the decreased expression of NGAL by siRNA had
opposite effects (18). Our results confirm that NGAL is a
surviving factor for cancer cells, and we extend these findings by
demonstrating that the protective effect of NGAL is mediated by
its ability to bind and transport iron. Our results are in agreement
with the model proposed by Devireddy et al. (17). In this model,
it is proposed that internalization of the apo form of NGAL leads
to iron loss and apoptosis. Conversely, internalization of iron-
loaded NGAL might prevent apoptosis.
Iron contributes to enzyme activity in DNA synthesis, metab-
olism, and oxygen response, and its acquisition plays a critical
role in development, cell growth, and survival (22). Cancer cells
have a higher requirement for iron than normal cells because
they rapidly proliferate. This is reflected by the evidence that
tumor cells have higher numbers of transferrin receptors on their
surface, mediating a high rate of iron uptake (24). The impor-
tance of keeping the levels of iron uptake constant is further
suggested by the evidence that multiple and redundant systems
for iron uptake and transport exist. Most cells acquire iron by
capturing iron-loaded transferrin. However, hypotransferrine-
mic mice (25, 26) and humans (27) have defects in central
nervous system development and hematopoiesis when most
epithelial organs are normal. Likewise, the mice lacking the
transferrin receptor 1 initiate organogenesis but succumb to
the effects of anemia (28). Given that iron is necessary for all
of the cells, there must be other pathways for iron acquisition
in epithelial cells. One such pathway is mediated by NGAL. In
our experimental model, we observed that cells knocked down
for NGAL expression showed a decrease of 20–30% iron
content, and that this decrease still allowed cell survival.
However, whether either the iron delivery was further de-
creased or cells were exposed to an appropriate stress, such as
serum deprivation, cells underwent apoptosis. Indeed, admin-
istration of iron, either as iron salt, transferrin, or iron-loaded
NGAL, restored the ability of knockdown cells to survive in
the absence of serum. Similarly, NGAL knockout mice are
vital and do not show gross developmental defects, although
they succumb to bacterial infection (29).
Many studies have demonstrated that iron chelators, such as
DFO, have effective anticancer activity (30). Iron is essential for
the catalytic activity of ribonucleotide reductase (an enzyme
mediating the conversion of all four ribonucleotides to their
deoxyribonucleotide counterparts), which is the rate-limiting
step of DNA synthesis (31). However, in our experimental
system, the proliferation rate of the cells knocked down for
NGAL expression is not affected (data not shown).
Iron levels strictly control the activity of specific prolyl hy-
droxylase-domain enzymes (PHDs), which, in turn, promote
functional activation of transcription factors involved in tumor
development, as is the case of the HIF-1, which controls genes
involved in energy metabolism and angiogenesis (32). HIF-1 is
primarily regulated by specific PHDs that initiate its degradation
via the vonHippel-Lindau tumor suppressor protein. The oxygen
and iron dependency of PHD activity accounts for regulation of
the pathway by both cellular oxygen and iron status. We have
evidence that in our experimental system, the protein level of
HIF-1 is increased in the NGAL knockdown clones and is
down-regulated by the addition of iron. Conversely, in control
cells, the level of HIF-1 protein is low and up-regulated by the
addition of DFO. Moreover, the activity of a HIF1-responsive
promoter parallels the level of HIF-1 protein (A.I., F.P., and
A. Leonardi, unpublished observation). Because NF-B is a
central component in the hypoxic response that positively reg-
ulates HIF-1 expression (33), it is tempting to speculate that the
involvement of NGAL as an iron transporter, and its opposing
effect on HIF-1 expression, could be a part of an auto-
regulatory loop that has inhibitory function between NF-B and
HIF-1 to control tumor progression.
Modulation of cell survival may not be the only way NGAL
inf luences the behavior of a cancer cell. NGAL has been
demonstrated to form a complex with MMP-9, playing a role
in the maintenance of an extracellular pool of a potentially
active form of the protease, whose activity is associated with
angiogenesis and tumor growth (16). This is supported by the
evidence that the level of NGAL expression correlates with the
clinical outcome of the patients and the depth of the tumor
invasion (17). We have evidence that a complex between
NGAL and MMP-9 also exists in transformed thyroid cells,
although neither the exact role that such a complex plays in
thyroid cancer, nor whether or not the activity of MMP-9 is
affected by the presence of NGAL, is known (A.I. and
A. Leonardi, unpublished observations).
In other experimental systems, NGAL has been shown to
induce expression of E-cadherin to promote formation of po-
larized epithelia and diminish invasiveness of ras-transformed
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Fig. 5. Intracellular iron content of the different FRO cell lines. Colorimetric
analysis of intracellular iron concentration is shown. Results were mean SD
of at least three separate experiments, performed in triplicate. Significantly
different from controls. *, P  0.05.
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cell lines (34). In our experimental system, NGAL seems to have
a different role. In fact, ectopic expression of NGAL in a normal
thyroid cell line, or its knockdown in transformed cells, does not
alter the expression of E-cadherin or vimentin (data not shown).
Our results, in addition to identifying NGAL as a potential
target for therapeutic intervention, also strengthen the rationale
for the use of iron chelators in the treatment of cancer. Depleting
iron from a rapidly dividing cancer cell through the implemen-
tation of iron chelators, or decreasing NGAL expression, de-
prives iron of a component critical for various cellular processes
and induces apoptosis.
Materials and Methods
Cell cultures and biological reagents, processing of conditioned media, two-
dimensional gel elecrophoresis, mass spectrometry analysis, immunohisto-
chemical analysis, Northern and Western blot experiments, in vitro and in vivo
tumorigenicity assays, measurements of apoptosis, quantification of iron
content, and statistical analysis were performed as described in the SI Text.
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